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11. Introduction
1.1 Gasoline and additives
Gasoline is a complex mixture of many constituents in varying proportions and
about 150-200 different compounds have been identified (168, 170). In gasoline
vapor, about 95% (by volume) of the components are various alkanes (e.g., n-
butane, isopentane, n-pentane and isobutane) and typically less than 2% are
aromatics (toluene, benzene and xylenes) (16, 66, 168, 170). Further, several
compounds are added to the gasoline e.g., antiknock, detergent, antirust,
antioxidant and anti-icing additives (77, 168). With the restrictions on use of lead
as an antiknock additive other means of octane enhancement are used today.
These include (in order of increasing cost) (113):
• the metallic additive, methylcyclopentadienyl manganese tricarbonyl
• changes in the refining process - increase of aromatics or alkenes
• addition of oxygen containing compounds (called oxygenates).
Use of the manganese compound is not approved in Europe (113), but in the USA
and Canada it is a source of manganese contamination (47, 177). Increasing the
amounts of aromatic compounds in gasoline has been the most common method,
but also the most controversial, due to the known carcinogenic effect of e.g.,
benzene (75, 113). Oxygenates as gasoline additives will be discussed in this
thesis.
Oxygenates enhance the octane number in gasoline and improve combustion,
thus reducing emissions (69, 160). Today, especially methyl tertiary-butyl ether
(MTBE) is used and the world-wide production has grown by 20% per year over
the last decade, particularly in North America and in Europe (1, 53). The total
production capacity was 21•109 kg MTBE in 1994 (53). Other aliphatic ethers,
such as ethyl tertiary-butyl ether (ETBE) and tertiary-amyl methyl ether (TAME)
or alcohols may be used as oxygenates. MTBE is usually added to unleaded
gasoline in quantities between 2 and 5% (by volume), to raise the octane level, or
up to 15% (by volume) to improve combustion efficiency (53, 69). The ethers are
preferred to alcohols as gasoline additives for instance because ethers do not
increase the volatility of the gasoline or cause problems with corrosion (27, 37).
However, these ethers themselves are highly volatile and the risk for human
exposure is mainly through inhalation. Occupational exposure to oxygenates
occurs mostly during handling of oxygenates alone or in combination with
gasoline. The general public is primarily exposed to oxygenates during gasoline
filling, but may be exposed to low levels of MTBE through the drinking water in
areas where the groundwater has been contaminated with MTBE from leaking
underground storage tanks (primarily reported from California, USA) (28, 69).
After the introduction of oxygenated fuels and the addition of MTBE to gasoline,
2complaints about acute health symptoms, e.g., headache, irritation and nausea,
have been reported in the USA (69, 160).
1.2 Toxicokinetics
Toxicological basic research, directed toward risk assessment relates to the
relationship between exposure, tissue dose, initial tissue interactions and toxic
responses. Two areas that are of key importance to make it possible to understand
and interpret toxicological information are:
• toxicokinetics, specifically defined as the uptake, distribution, metabolism
(biotransformation) and excretion of a chemical in the body and
• toxicodynamics, the mechanism of action of a compound or its metabolites and
their potency at the site of action.
Kinetics (from Greek for motion or movement) in this field is defined as the
mathematical description of the time-course of chemicals in living organisms.
One of the rationales for a toxicokinetic study is that the response in a target
tissue should be related to the concentration profile of the parent compound or
metabolites in that particular tissue. In animals it is possible to sample different
tissues to measure the concentration of a compound. This is often not possible in
humans. Instead computer models have been developed and used to estimate
tissue doses and toxicokinetics in situations when measured data cannot be
obtained e.g., to extrapolate from exposed animals to humans. Physiologically
based toxicokinetic (PBTK) models are especially useful, since PBTK models are
based on actual organ volumes and blood flows in individual tissues. A PBTK
model consist of several compartments where organs are grouped together
according to blood flow and fat content. Mathematical differential equations are
applied on data from actual physiological tissue blood flow and organ volumes
and tissue/blood partition coefficients to describe the fate of the chemical in the
body (7, 84).
1.3 Biological Monitoring
Sometimes it may be more relevant to measure the absorbed dose (internal
exposure or body burden) than to analyze the exposure dose (e.g. external air
level). Biological exposure monitoring should be considered complementary to air
monitoring and should be conducted when it offers an advantage over air
monitoring alone. Further, biological monitoring should be used to e.g., validate
air monitoring, to test the efficiency of personal protective equipment, to
determine absorption via the skin and the gastrointestinal system, to detect non-
occupational exposure or when physically demanding work is performed. The
individual exposure is usually determined from levels in blood, urine or expired
air and a biological exposure marker (biomarker) adjusts for dermal absorption
and individual factors that may influence the uptake of a chemical (e.g. non-
3occupational exposure, metabolic ability, diet, physical activity, body build, age,
alcohol intake and smoking) (106, 144).
42. The Present Thesis
2.1 Background
An exposure chamber (20 m3) with controlled climate is at our disposal in the
laboratory and it is therefore possible to perform well-defined controlled
experiments in which humans are exposed to a substance through the air they
breath. During these experimental exposure studies, the toxicokinetics (uptake,
distribution, metabolism and excretion) are studied quantitatively, and in addition,
potential acute effects are measured during and after the exposure. This present
thesis applies primarily to human toxicokinetics, but also to acute effects of the
two fuel additives MTBE and ETBE.
At the time the MTBE study were initiated there was no data on the
toxicokinetics in humans despite an increasing industrial use of MTBE. Further,
complaints about acute health effects (headache, nausea, nasal irritation and eye
irritation) have been associated with MTBE, since they appear to have emerged
after the addition of MTBE to gasoline (69, 120).
The ETBE research project was initiated since it was considered essential that
the uptake, disposition and acute effects of ETBE in humans should be explored
before this oxygenate was introduced on a broad scale as an additive to gasoline.
One reason for the interest in ETBE in Sweden is the potential to increase the
market for renewable fuels, as ETBE is produced from bioethanol.
A further goal in performing these studies was to address the issue of biological
exposure monitoring. The unmetabolized ethers or some metabolites may be
useful biomarkers for exposure to gasoline vapor as these ethers, added in
controlled amounts to gasoline, are highly volatile. Biomarkers already exist for
the less volatile compounds predominantly present in liquid gasoline, e.g., for
benzene there are several biomarkers including e.g. trans, trans-muconic acid
(128) and for trimethylbenzenes dimethylhippuric acids is proposed (89).
However, no suitable biomarker for the vapor phase of gasoline has yet been
characterized.
2.2 Aims
The main purposes of this thesis were to study the uptake, distribution,
metabolism and excretion of MTBE and ETBE in humans, to address the issue of
biological monitoring and, in addition, to characterize acute effects during and
after the exposure to these ethers.
More specifically, the aims of these studies were to:
5• Study the inhalation toxicokinetics, i.e. the respiratory uptake, distribution,
metabolism and excretion of MTBE, ETBE and of their common metabolite,
tertiary-butyl alcohol (TBA), respectively (Studies I and II).
• Map additional metabolites of MTBE in urine (Study III).
• Determine partition coefficients of MTBE, ETBE, TAME and TBA (Study IV).
• Develop a physiologically based toxicokinetic (PBTK) model for inhalation
exposure to ETBE (Study V) using the partition coefficients (Study IV) and
experimental kinetic data (Study II).
• Use the PBTK model to address the issue of biological exposure monitoring
(Study V).
• Screen acute effects of MTBE and ETBE by symptoms questionnaire and by
objective measures of eye and nasal irritation (Studies VI and VII) and lung
function (Study VII).
63. Review of the Literature on Methyl and
Ethyl tertiary-Butyl Ether
Several reviews discussing the toxicity and acute effects of MTBE are available
(42, 53, 69, 104, 160). No major work related to health effects of ETBE has been
published. The following chapter will give a brief summary of the physical
properties, toxicity and biological effects of MTBE and ETBE.
3.1 Chemical Structure, Nomenclature and Physical Properties
MTBE and ETBE are aliphatic branched ethers with the molecular formulas
C5H12O and C6H14O, respectively (Figure 1). These ethers are colorless and
inflammable liquids at room temperature. Further, the ethers have a distinct smell
with a low odor threshold (69, 135). The taste threshold is also low for the ethers
and mixed in water the taste threshold is 47 ppb for ETBE and 134 ppb for
MTBE (69). Chemical and physical properties of MTBE and ETBE are
summarized in Table 1.
Highly branched ethers have much less peroxide formation after UV-light
exposure compared with unbranched ethers. Hence, ETBE has a somewhat higher
formation of peroxides compared to MTBE (37, 54, 115).
Table 1.
 Chemical and physical properties of MTBE and ETBE (30, 34).
MTBE ETBE
CAS number 1634-04-4 637-92-3
Synonyms Methyl tertiary-butyl ether,
MTBE
2-metoxy-2-methylpropane,
methyl tert-butyl oxide,
tert-butyl methyl ether,
methyl-1,1-dimethylethyl ether,
1,1-dimethylethyl metyl ether
Ethyl tertiary-butyl ether,
ETBE
2-etoxy-2-methylpropane,
ethyl tert-butyl oxide,
tert-butyl ethyl ether,
ethyl 1,1-dimethylethyl ether,
1,1-dimethylethyl etyl ether
Molecular weight (g/mol) 88.15 102.18
Density (g/cm3) 0.7404 (20°C) 0.7364 (25°C)
Boiling point (°C) 55.2 73
Vapor pressure (kPa) 32.7 (25°C) 17.3 (25°C)
Water solubility
(g/100gwater)
4.8 1.2
Odor detection threshold
(ppb)
53 13
Conversion factor
(20°C, 101.3 kPa)
1 ppm = 3.60 mg/m3                   
1 mg/m3= 0.278 ppm
1 ppm = 4.24 mg/m3                  
1 mg/m3 = 0.236 ppm
7Methyl tertiary-butyl ether (MTBE)
C
CH3
CH3 O CH3
CH3
Ethyl tertiary-butyl ether (ETBE)
C
CH3
CH3 O C2H5
CH3
Figure 1.
 Structural formulas of MTBE and ETBE.
3.2 Occurrence
The first large scale production of MTBE started in Italy around 1975, followed
by production units in Germany and the USA (27, 69). Today, MTBE is
manufactured world-wide from methanol (mainly from natural gas) and isobutene
(from petroleum refinery sources or from dehydration of tertiary-butyl alcohol) to
a very large extent. The production of MTBE was 21•109 kg in 1994 and is
increasing (53). In Sweden, 37•106 kg of MTBE was produced during 1996, and
an additional 33•106 kg was imported (137).
MTBE is the most used oxygenate in motor fuel, however TAME has been in
use in Finland since 1995 (145). In Sweden, with an interest in the potential for
renewable fuel sources, the replacement of MTBE with ETBE has been
suggested. ETBE can be manufactured from ethanol (obtained from agricultural
and forestry products) and isobutene.
Since 1981, MTBE has been used therapeutically in humans to dissolve
gallstones (3, 70, 83, 99). Further, MTBE has been used as a eluent in liquid and
thin-layer chromatography (103, 124) and as solvent in the determination of resin
and fatty acids in pulp mill effluents (173).
3.2.1 Oxygenates in Gasoline
Oxygenates are released to the atmosphere during the manufacture and
distribution of oxygenated fuels, in the vehicle-refueling process and from
evaporative and, to a lesser extent, exhaust emissions from motor vehicles.
In the USA, the Clean Air Act Amendments of 1970 initiated a commitment by
the US Government to reduce exposure of the general population to air pollutants
that may cause adverse health effects. A further step was taken later on toward
reducing motor vehicle emissions, and fuel reformulations with oxygenates
started to be used. Oxygenates increase the octane number and improve the
combustion efficiency and reduce emissions (69, 160). The reduction of carbon
monoxide (CO) is a main argument for the use of MTBE in the USA. MTBE has
been put to more widespread use after the legislation of the Clean Air Act,
especially in the winter when levels of automotive CO emissions are higher.
Typically, the maximum allowed oxygen content in gasoline is 2.7% by weight,
8corresponding to 15% MTBE or 17% ETBE by volume (69), but in Sweden is the
maximum allowed oxygen content in gasoline 2% oxygen by weight (27). In
Sweden, the use of oxygenates was mainly introduced when lead was outlawed
from gasoline starting in 1986 when an extra tax was added on gasoline
containing lead (27). Other reasons for the use of oxygenates in Sweden have
been to decrease the oil dependence and decrease those emissions that might
cause adverse health and environmental effects. Further, if ETBE is going to be
used a decrease of the emission of fossil carbon dioxide is initiated.
Examples of environmental and health observations related to oxygenates in
motor fuels are given bellow:
• The total level of toxic air pollutants decreases with the addition of oxygenates
to gasoline, but levels of specific toxic substances in air may increase.
Oxygenates in motor fuel decrease the emission of CO, aromatic compounds,
e.g. benzene, and, in addition, 1,3-butadiene and ozone (69, 150). However, an
increase in the emissions of aldehydes (formaldehyde or acetaldehyde from
MTBE and ETBE respectively) is seen after the addition of oxygenates in the
gasoline (69, 110, 150).
• Oxygenates cause a substantial reduction in the odor detection threshold of
various gasoline blends (69, 150).
• The main atmospheric fate of the ethers is probably a reaction between
hydroxyl-radicals and the ether (161). A number of degradation products have
been identified: the primary products are tertiary-butyl formate, formaldehyde
(from MTBE), acetaldehyde (from ETBE), methyl acetate and acetone (91,
157). In the soil, biodegradation of the oxygenates by microorganisms has been
shown (118, 151).
• Complaints about acute health effects (headache, nausea, nasal irritation and eye
irritation) have been associated with the exposure to gasoline containing MTBE
(further described in section 3.5) (69, 120).
• Neoplasia in animals (liver tumors in female mice, kidney and testicular tumors
in male rats) have been reported after high and chronic exposures to MTBE
(further described in section 3.4) (15, 21).
3.2.2 Occupational and Non-Occupational Exposure
Oxygenates are highly volatile and exposure is therefore mainly via the air.
People exposed occupationally to oxygenates include clinical laboratory
technicians, production testers, workers involved in transport of oxygenates,
gasoline station attendants and professional drivers (69, 170). Commuters, drivers
who pump gasoline and people who live or work near service stations and plants,
and, in addition, gallstone patients and health care workers may also be exposed
to oxygenates (3, 70, 83, 99).
9Table 2.
 Occupational exposure and exposure of the general public to MTBE (69). Peak
exposure (range) and median values are given.
Neat MTBE MTBE in gasoline
Peak
(ppm)
Median values
(ppm)
Peak
(ppm)
Median values
(ppm)
Manufacturing 0.01-250 0.03 d - -
Blending 0.01-97 2.2 d 0-100 0.04 d
Transport 0.03-1000 0.2 d 0.001-510 0.1 d
Distribution - - 0-14 0.1 d
Service station attendants - - 0.3-140 b 0.3-5.8 b
0.2-0.6 d
Mechanics - - 0.3-32 0.1 d
Refueling - - 0-38 a 0.4-5.8 a
In automobile while refueling - - 0.006-0.17 0.02-0.04 d
Automobile cabin for commuters - - 0.002-0.02 0.005 c
Community air - - 0-0.004 0.00013 e
a
 exposure during 1-2 min.
b
 exposure during less than 30 min.
c
 median during 1 h.
d
 median during 6-9 h.
e
 median during 24 h.
The exposure to gasoline and oxygenates at gas stations and during loading of
gasoline are generally reduced when a vapor recovery system is used (16, 65, 67,
149). A review of MTBE exposure studies performed in the USA is presented in a
document from Health Effect Institute (69) and summarized in Table 2.
3.3 Toxicokinetics
No toxicokinetic studies in humans were available when this thesis work was
initiated. In the following chapter, work from the thesis is not cited.
3.3.1 Uptake
The predominant uptake of oxygenates is via inhalation. Absorption through the
skin and from the gastrointestinal tract does occur, mainly when potable water is
contaminated with MTBE (138). In a Finnish study, the absorption after
inhalation is reported to be approximately 40% of the MTBE dose after a 4 h
exposure at rest (130).
In rats, the absorption through the gastrointestinal tract is fast and complete,
whereas the dermal absorption is low (116, 121).
3.3.2 Metabolism
MTBE is metabolized to tertiary-butyl alcohol (TBA) and formaldehyde, and
ETBE is metabolized to TBA and acetaldehyde, by oxidative demethylation
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(Figure 2). MTBE and TBA have been detected in human blood, exhaled air,
urine and breast milk after experimental, clinical and environmental MTBE
exposures (29, 33, 67, 99, 119, 120, 130, 166).
In vitro experiments using rat liver microsomes show that MTBE is
metabolized to TBA and formaldehyde (26) and in addition, TBA is
biotransformed to formaldehyde (36). Further, it has been reported that MTBE
and ETBE are metabolized to TBA in rats (23, 26, 116, 147). Four additional
metabolites have been detected in rats exposed to carbon-14 labeled MTBE and
two metabolites were identified as α-hydroxyisobutyric acid (HBA) and 2-
methyl-1,2-propanediol (MPD) (116). In a recent study, rats were exposed to
2000 ppm MTBE or 2000 ppm ETBE during 6 h and three major metabolites,
HBA, MPD and an unidentified conjugate of TBA were found in addition to low
levels of TBA, acetone and another TBA-conjugate (17). All these metabolites
have also been detected in rats exposed to labeled TBA (13, 17).
MTBE activates UDP-glucuronosyltransferase and P450 isoenzymes 2B1, 2A6
and 2E1 in liver microsomes from both man and rats (26, 74, 147, 158). The
metabolic activity, measured as the formation of TBA from MTBE in microsomes
from different organs of rats, was found to be markedly higher in the nasal
mucosa compared with the liver (73).
3.3.3 Distribution
Linear kinetics have been seen in blood of rats exposed for 2 weeks to MTBE at
50 ppm to 300 ppm in the air (147). In humans, linear kinetics have been reported
after 4 h exposure to up to 75 ppm MTBE (130).
The MTBE level in blood increases rapidly during exposure and decreases soon
after the exposure ends (29, 33, 130, 135). In contrast, the concentration in blood
of the first metabolite, TBA, increases slowly and a plateau is reached after the
exposure. The levels start to decrease slowly approximately 2-4 h after the
exposure (29, 130, 135). The same distribution pattern has been seen in patients
exposed to MTBE through the gallbladder (99). MTBE was found to be exhaled,
distributed to fatty tissues and excreted in urine together with TBA. In addition,
MTBE and TBA have been detected in breast milk at levels only slightly lower
than the concentration in blood.
3.3.4 Excretion
Of the MTBE taken up by the lung in humans, about 58% was eliminated
unchanged to the air, 1.4% in urine and less than 1.2% as TBA in the urine (130).
The excretion of carbon-14 labeled MTBE in rats was fast and independent of
sex and delivery route (116). After intravenous administration (40 mg MTBE/kg
bw), 60% was eliminated through the lungs (90% of this fraction within 3 h post
exposure) and 35% in the urine (70% within 24 h and 90% within 48 h post
exposure). Only minor amounts were recovered in feces (2%) and tissues (0.4%).
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At higher MTBE doses (8000 ppm and 400 mg/kg bw), the fraction recovered
decreased in urine and increased in exhaled air. In another study (176), mice that
were given MTBE intraperitoneally (50-500 mg/kg bw) eliminated 23-69% of the
dose as MTBE through the lungs, and most of this fraction (90%) within 3 h.
In a study reported in a conference abstract, rats and mice were exposed to
carbon-14 labeled ETBE at a low level (500 ppm, 6 h exposure) after which most
of the radioactivity was eliminated in the urine (23). However, at a higher
exposure level (5000 ppm, 6 h), rats eliminated most of the ETBE in exhaled air,
whereas mice eliminated equal parts in urine and exhaled air. Furthermore, rats
repeatedly exposed to ETBE have higher urinary levels of TBA compared with
rats exposed only once.
These MTBE and ETBE studies implies that saturable metabolism, enzyme
induction or inhibition occurs at high exposure levels.
ETBE
C
CH3
CH3 O C2H5
CH3
2-methyl-1,2-propanediol (MPD)
tertiary-butyl alcohol (TBA)
C
CH3
CH2OH
C
CH3
CH3 O
acetone
+ CH2 O
formaldehyde
CO2
C
CH3
COOH
OH
CH3
CH3
α-hydroxyisobutyric acid (HBA)
+
acetone
CO2
OH
C
CH3
CH3
CH3 OH
C
CH3
CH3 O
acetaldehyde
CH2OCO2
COCH3 CH2OH
COCH3 CHO
CHOHCH3 COOH
acetol
methylglyoxal
D-lactate
COCH3 COOH
CHOHCH3 COOH
CH3 CH2OH
1,2-propanediol
L-lactate
pyruvate
glucose
C
CH3
CH3 O CH3
CH3
MTBE
CO2
formaldehyde
CH3 C H
O
CHOH
Conjugation
Conjugation
Conjugation
Figure 2. Potential metabolism of MTBE and ETBE (69, 98). The parent ethers and
metabolites that are mainly dealt with in the present thesis are marked with bold.
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3.4 Toxicity in Animals and In Vitro Tests
The LD50-value for MTBE in mice is 4 g/kg (103) and for ETBE in rats >5 g/kg
(123). The LC50-value in mice after 15-min inhalation exposure is 39000 ppm for
MTBE and 29000 ppm for ETBE (109). This implies low acute oral toxicity of
MTBE and ETBE.
Acute and reversible neurotoxic effects (e.g., eyelid twitching, hypoactivity,
lack of startle reflex, labored respiration and ataxia) have been seen after short
term (45, 164), subchronic (50, 102, 112, 167) and chronic (21) exposure to high
levels of MTBE and ETBE.
The concentration of α2u-globulin increased in male rats after MTBE and ETBE
inhalation exposure and, in addition, after exposure to TBA in drinking water
(100, 136, 171). The toxic syndrome, referred to as α2u-globulin nephropathy, is
well known in male rats. The low molecular weight protein, α2u-globulin, is
synthesized in the liver under androgen control. Characteristic symptoms include
a progressive increase of the size and number of protein droplets in the kidney,
which can progress to mild tubular degeneration, necrosis and scattered foci of
tubular regeneration (24, 148). These changes have also been reported after
exposure to unleaded gasoline (107) and isoparaffinic fractions of unleaded
gasoline, e.g. 2,2,4-trimethylpentane (148).
In mice, a reversible decrease in the breathing frequency is seen during the first
5-10 min of a 1 h exposure to 83-2800 ppm MTBE (155). At a higher exposure
level, 8300 ppm MTBE, the breathing frequency is decreasing during the entire
exposure, which according to the authors indicate both sensory and pulmonary
irritation. However, cells recovered in lung lavage did not show any
morphological or biochemical changes.
Since MTBE is used in medical treatment, tissue injury has been studied in rats
after injection of MTBE into the hepatic parenchyma and after intravenous and
intraperitoneal administration (2). MTBE was found to induce local tissue damage
and could cause severe lung injury when infused into a large vein.
In unpublished studies (11, 121, 122), dermal tests of MTBE and ETBE caused
reversible erythema and edema in rabbits. However, the authors did not consider
MTBE to be a primary skin irritant whereas ETBE seemed to give a slightly
higher degree of irritation. Further, ocular tests were performed and eye redness
was found in rabbits after application of 0.1 ml MTBE or ETBE. The irritation
was reversible and the eyes were normal 3 days after MTBE and one to two
weeks after the ETBE exposure. No sensibilization was seen in guinea pigs after
ten intradermal injections of 0.5 ml MTBE (0.1%) (11).
Mutagenicity tests for MTBE (108, 111, 141) and ETBE (178) have been
predominantly negative. Neither MTBE nor ETBE showed genotoxic effects in
bone marrow micronucleus tests (38, 90, 111, 164), in chromosome aberration or
in forward mutation assays (38, 90, 108, 163, 165) with or without the addition of
metabolic enzymes. In the evaluation of the toxicity of MTBE and ETBE using a
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structure relational models, no genotoxicity or carcinogenicity could be predicted
(142, 179).
Chronic inhalation exposure of MTBE resulted in an increased incidence in
kidney tumors in male rats (3000 ppm) and in liver tumors in female mice (8000
ppm) (21). In another study, chronic exposure (up to 1000 mg MTBE/kg bw)
increased the incidence of Leydig cell tumors in male rats and the incidence of
leukemia and lymphoma in female rats (15). This latter study has been criticized
for the incomplete descriptions of methods and results: Leydig cell tumors were
common also in the control material (i.e. the increase might be random) and only
combined data on leukemia and lymphoma were reported (results were not
presented for each respective neoplasm) (114).
MTBE tested negative for teratogenic and reproductive effects in rabbits and
rats up to 8000 ppm and in mice up to 1000 ppm (18, 19, 20, 41).
No studies showing cancinogenic effects or effects on reproduction after ETBE
exposure in animals have been published.
MTBE and ETBE are metabolized to at least two intermediates each that are
suspected carcinogens in rodents. TBA causes kidney tumors in male rats and
thyroid gland adenomas in mice exposed to high concentrations in drinking water
(39). Formaldehyde is genotoxic in a wide variety of in vitro assays and
carcinomas have been reported in the nose of rats at high exposure levels (78).
Acetaldehyde is genotoxic in in vitro assays and may cause cancer in the upper
airways of rodents (76). No data on carcinogenic potential is available for other
metabolites, e.g., HBA and MPD.
3.5 Health Effects in Humans
In Fairbanks, Alaska, acute health effects have been reported during the use of
oxygenated gasoline (MTBE) (120). Different symptoms, e.g., headache, nausea,
nasal irritation and eye irritation were common: among 18 workers exposed to an
average of 0.1 ppm MTBE (air measurements) between 5 and 13 reported one or
more of a variety of symptoms. These workers had an average concentration of
0.02 µM MTBE in blood. At a follow-up three months later (no MTBE in the
gasoline), only up to 2 among 28 gasoline-exposed subjects reported symptoms.
At that time, 0.04 ppm MTBE was detected in air (8 h average) and MTBE levels
in blood averaged 0.003 µM from the studied individuals. In another study,
subjects with high levels of MTBE in the blood (>0.03 µM MTBE) after a
workshift, reported one or more symptoms more frequently than subjects with
lower levels of MTBE in the blood (166). Other epidemiological studies have
failed to show any correlation between rating of acute health effects and MTBE
exposure levels (8, 57, 61, 64, 119). The above mentioned study in Fairbanks has
been criticized because several factors may have influenced the ratings, e.g. the
change in gasoline odor, lower odor threshold, winter climate, outbreaks of
complaints due to increase in gasoline price, and media reports (53, 69, 160).
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Headache, dizziness, nausea, and dyspnea were reported in a family of five
individuals who were exposed to water contaminated by gasoline. The levels of
MTBE found in the well water analysis were 1.3 to 1.6 mg/l and the family used
the water for everything except drinking. In a double-blind test, all members of
this family indicated MTBE as the most objectionable odor of several other
compounds existing in gasoline (9).
The majority of human MTBE studies relate to the percutaneous transhepatic
catheterization of the gallbladder and direct dissolution of gallstones with MTBE
(70, 83, 99, 134, 156). In this medical procedure MTBE is continuously supplied
in amounts that fill the gallbladder (1-15 cm3) for up to 6 h/day for 1 to 3 days.
Mild acute side effects (nausea, vomiting, and abdominal discomfort) have been
reported. Overflow of MTBE during instillation has been associated with sedation
(reversible coma in one patient), unpleasant odor of MTBE in the breath, low
blood pressure, acute renal failure and mild duodenitis.
No acute effects (rated symptoms or objectively measured nasal or eye
irritation) were observed in healthy volunteers experimentally exposed to up to
1.7 ppm MTBE for 1 h at rest (n=80) (33, 135). In a Finnish experimental study,
thirteen males were exposed to 0, 25 and 75 ppm MTBE for 4 h (140). In this
study, measurements of subjective symptoms and mood as well as reaction time
and posturography (body sway) were performed during the exposure (1 and 3 h)
and at 1 h post exposure. At 75 ppm MTBE, mild symptoms such as “heaviness in
the head” and mild mucous membrane irritation were reported after 3 h of
exposure, but the symptoms had disappeared 1 h post exposure. In total 6 out of
13 subjects reported MTBE-related symptoms.
No reports on the health effects of ETBE have been published.
3.6 Occupational Exposure Limits and Classifications
The present Swedish occupational exposure limit (OEL) for MTBE is 50 ppm or
180 mg/m3 during an 8 h work day (10, 104). The short-time limit (15 min) is 75
ppm or 270 mg/m3. No OEL value for ETBE is available in Sweden (December
1998).
OEL values for MTBE have recently been established in several countries
(listed in Table 3), whereas it is still under evaluation in e.g. Germany (48). At
present, the lowest 8 h time-weighted average (TWA) value has been adopted in
the United Kingdom (68). In the International Labour Office summary list for the
year 1991 (81), Czechoslovakia and the Soviet Union were included. No OELs
for ETBE has been found in the literature.
The categorization of MTBE and some metabolites by the National Board of
Occupational Safety and Health in Sweden (10), the International Agency for
Research on Cancer (IARC) (76, 78) and the American Conference of
Governmental Industrial Hygienists (ACGIH) (5) is summarized in Table 4.
ACGIH has classified MTBE as a confirmed animal carcinogen with unknown
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Table 3.
 The time-weighted average value during an 8 h work day and the short-time
exposure value (15 min time-weighted average exposure) for MTBE.
Country Time-weighted average value
(ppm)
Short-term exposure value
(ppm)
Sweden (10, 104) 50 75
Finland (159) 50 -
the Netherlands (117) 50 100
the USA (5) 40 -
United Kingdom (68) 25 -
Czechoslovakia (81) 28 56
Soviet Union (81) - 28
relevance to humans (A3) based on animal studies and inadequate (or no) data
from epidemiological studies. Gasoline vapors have been classified by IARC as
“possibly carcinogen to humans”, based mainly on the established carcinogenicity
of some constituents such as benzene and 1,3-butadiene (77). The following are
known for humans of the three metabolites, TBA, formaldehyde and
acetaldehyde:
• The carcinogenicity of TBA in humans has not been evaluated. TBA has an
OEL in Sweden, but is not classified as a carcinogen in the OEL list (10) or by
the IARC. TBA is categorized by ACGIH (5) as a non classifiable human
carcinogen (A4), based on inadequate data.
• Formaldehyde occurs as a natural product in most living systems and in the
environment, e.g., from cigarette smoke. For the highly reactive formaldehyde
an increase in relative risk for nasopharyngeal cancer was associated with
occupational exposure (78). The IARC evaluation of formaldehyde is based on
“limited evidence in humans for carcinogenicity and sufficient evidence of
carcinogenicity in experimental animals”.
• The IARC evaluation of acetaldehyde is “inadequate evidence for
carcinogenicity to humans and sufficient evidence for carcinogenicity in
animals”.
Table 4.
 Summary of classification of MTBE and some metabolites.
Sweden IARC ACGIH
MTBE - - A3 c
TBA - - A4 c
Formaldehyde C and D a 2A b A2 c
Acetaldehyde C a 2B b A3 c
a
 classified as a human carcinogen (Group C) and sensibility agent (Group D) (10)
b
 classified as a probably carcinogenic agent to humans (Group 2A) and possibly carcinogenic
agent to humans (Group 2B) (76, 78)
c classified as a suspected human carcinogen (A2), animal carcinogen (A3) and not classifiable as
a human carcinogen (A4) (5).
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4. Methods
An overview of the methods used is given in this section, however, all details are
further described in the original papers.
The human exposures were performed according to the Helsinki Declaration,
after approval from the regional ethical committee at the Karolinska Institute,
Solna, Sweden and after informed consent (verbal and written) from the subjects.
4.1 Whole-Body (Studies I and II) and Face-Mask (Study III)
Exposures
Healthy male volunteers were exposed to MTBE (n=10, Study I) or ETBE (n=8,
Study II) in a 20 m3 exposure chamber (Figure 3). Two subjects were exposed at a
time and different subjects participated in the MTBE and ETBE studies. In study
III, four out of the ten subjects that participated in the MTBE study were exposed
to 13C-labeled MTBE ([1,2-13C2]-MTBE). These volunteers were exposed via a
face-mask and one subject at a time (Figure 4).
Figure 3. Inhalation exposure of MTBE or ETBE vapor in a 20 m3 chamber with
controlled climate. The two volunteers performed light physical exercise on bicycle
ergometers during the entire exposure and capillary blood samples were taken outside the
chamber.
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The chamber exposures (Studies I and II) were conducted during 2 h at the
nominal levels of 5, 25 and 50 ppm MTBE or ETBE and in addition, 0 ppm
(clean air) in the ETBE study. A pump transferred the liquid MTBE solution to a
preheated glass tube, where MTBE was vaporized and the completely vaporized
solvent followed the influent air stream into the exposure chamber. The
concentrations of MTBE or ETBE in the chamber air were monitored at 5-min
intervals by a Fourier transform infrared spectrophotometer (MTBE) and by a gas
chromatograph (GC) equipped with a gas sample injection loop (ETBE). The
chamber climate was carefully controlled with an average temperature of 19-
20°C, a relative humidity of 40-43% and 16-19 air changes per hour. To prevent
leakage of solvent, the air pressure in the chamber was kept about 5 Pa lower than
in the surrounding laboratory.
In the face-mask inhalation study (Study III), volunteers were exposed for 2 h
from polyester-laminated aluminum foil bags containing 180-200 liter air and 50
ppm 13C-labeled MTBE vapor (analyzed by GC). During the entire exposure, the
subject wore a breathing mask fitted with separated inlet and outlet valves. The
inlet valve of the breathing mask was connected to the exposure bag, which was
attached on the outside of the chamber (Figure 4). In this study, the volunteers
performed the exercise inside the chamber during the exposure because: i) the
chamber had controlled climate, ii) for practical reasons, as there was insufficient
space in the surrounding laboratory and iii) since all equipment for the exhaled air
analysis was fixed on the chamber wall.
     
Figure 4.
 Exposure to 13C-labeled MTBE vapor (via a face-mask) from exposure bags.
The volunteer wore a breathing mask during the entire 2 h exposure and performed light
exercise on a bicycle.
18
The highest exposure level (50 ppm MTBE and ETBE) was chosen considering
the current Swedish OEL value for MTBE (10) in both studies, since no
restrictions have yet been assigned to ETBE. There was at least two weeks
between successive exposures (Study I and II) and all subjects were unaware of
the actual exposure sequence. During all exposures, the subjects performed light
physical exercise (50W) on a computer-controlled bicycle ergometer and heart
rate, pedal frequency, workload and speed were recorded every 20 seconds.
Further, the individual pulmonary ventilation and respiratory frequency were
recorded as one-minute averages during the entire [1,2-13C2]-MTBE exposure and
during each 5-6 min exhalation period of MTBE, ETBE and post exposure of all
exposures.
4.2 Toxicokinetics of MTBE and ETBE (Studies I, II and III)
4.2.1 Sampling and chemical analysis of exhaled air, blood and urine
Identical time points for collecting blood, urine and exhaled air were used in all
exposure studies (Studies I, II and III).
Exhaled air was collected through a mouthpiece (Figure 5), fitted to two valves
with separate in and outlets (Studies I and II). Each exhalation period lasted for 5-
6 min and the exhaled air was analyzed during the last 2 min. MTBE in exhaled
air was analyzed by a Fourier transform infrared spectrophotometer (Study I) and
ETBE (Study II) and MTBE (Study III) by a GC equipped with a gas sample
injection loop.
After the exposure exhaled air was collected on adsorbent tubes. In study I, the
adsorbent was eluted with carbon disulfide and MTBE was analyzed with GC. In
studies II and III, the adsorbent tubes were desorbed in an automatic thermal
desorption unit and ETBE, MTBE and TBA were analyzed with a GC.
Figure 5. Sampling of exhaled air
every 30 min (5 min each time) during
the 2 h whole-body exposure to MTBE
and ETBE. Physical exercise was
performed on a bicycle ergometer
during exposure and pulmonary
ventilation and breathing frequency
were measured with a spirometer.
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Figure 6. Capillary blood sampled on the outside of the chamber and inside a glove box,
which was flushed with clean air.
Capillary blood was sampled from the fingertips of the volunteers (Figure 6)
before, during and up to 46 h after the MTBE and ETBE exposures and up to 20 h
after the [1,2-13C2]-MTBE exposure. In total, 23-24 blood samples were collected
and MTBE and TBA (Study I), ETBE, TBA and acetone (Study II) and MTBE,
TBA and acetone (Study III) were analyzed by head-space GC.
All urine was collected until 24 h post exposure (Studies I, II and III) and in
addition, a spot urine sample was collected at 46 h post exposure (Studies I and
II). After recording the volume, the urine samples were analyzed in the same way
as the blood samples
4.2.1 Calculations
Individual kinetic calculations were performed on data from all exposures. Each
subjects concentrations of MTBE and ETBE in blood versus sampling time were
fitted to a linear kinetic four compartment mamillary model with zero-order input
and first-order elimination (metabolism and excretion) in the central
compartment. Thus, other ways of elimination, e.g., renal clearance were
considered negligible, as well as skin uptake. Additional input data were net
uptake, time of exposure and the amount exhaled post exposure. The model was
written as an Excel spreadsheet macro (Johanson, unpublished). In fitting the
model to the exposure data, optimization was carried out by finding the most
likely values of rate constants by minimizing the unweighted residual sum of
squares using the Solver add-in macro in Microsoft Excel.
In the calculations the absorbed dose was regarded as the sum of the net
respiratory uptake and the amount exhaled during exposure. Previously in studies
of this kind, the absorbed dose (net respiratory uptake) has been estimated as the
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difference between the concentration of the chemical in inhaled and exhaled air,
multiplied by the pulmonary ventilation. However, by inclusion of the exhalation
during exposure, dose related parameters (such as clearance) become independent
of the length of exposure and a more accurate estimation of body burden was
achieved. Thus, absorbed dose in the present studies was referred to in two ways:
the respiratory uptake and the net respiratory uptake (previous approach).
Decay curves of MTBE and ETBE in urine (starting at 2-4 h) were fitted to
biexponential functions by nonlinear regression analysis using Solver in Microsoft
Excel. Data from the elimination phase of TBA in blood and urine, starting
approximately at 6 h, were fitted to a monoexponential function again by
nonlinear regression analysis.
The concentrations of MTBE and ETBE in blood at steady state was calculated
as the respiratory uptake rate divided by the total clearance. The area under the
concentration-time curve (AUC) of ETBE in blood was obtained from the four-
compartment model, while the AUC of TBA and acetone was calculated by the
trapezoidal rule. The renal clearance of TBA was calculated as the total amount of
TBA excreted in urine divided by the AUC of TBA in blood.
The toxicokinetics after the face-mask exposure (Study III) was analyzed (as
described above) and compared with the previous whole-body exposure (Study I).
4.3 Characterization of Metabolites in Urine by 13C NMR
Spectroscopy (Study III)
The natural abundance of the stable isotope 13C is 1.1%, and thus, 1.1% of carbon
atoms in compounds excreted in normal urine give usually single resonance in
NMR-spectra (one 13C-labeled). Thus, adjacent 13C atoms give multiple signals in
NMR-spectra as a result of carbon-carbon coupling and the natural probability of
that is 0.01%. The subjects in this study were exposed to MTBE that was 99%
13C-enriched at two adjacent carbons (i.e. doublet signals in the NMR spectra) at
the center carbon (C*, called b) and at one of the three CH3-groups (*CH3, called
a or c). Since only one of the three methyl groups was labeled three chemically
identical metabolites were formed, but with two different labeled structures
(marked with or without prime in Figure 14).
1H-Decoupled carbon-13 nuclear magnetic resonance (NMR) spectra were
obtained for urine samples collected prior to the [1,2-13C2]-MTBE exposure and at
2, 4, 7, 11, and 20 h post exposure (Study III). The urine was treated in two ways:
diluted in D2O and concentrated after protein precipitation. The latter was done to
concentrate the sample and reduce the signal to noise ratio in the NMR spectra.
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4.4 Determination of Partition Coefficients (Study IV)
The kinetics of a volatile substance depends largely on the partitioning between
blood and air and blood and other tissues. By definition, the partition coefficient
(λ) of a compound is the quotient of the concentration (C) in two different phases
at equilibrium (146):
λliquid/air = Cliquid / Cair
Liquid/air partition coefficients were determined in vitro by a closed vial
equilibration method previously described by Sato et al. (146) and used to
determine partition coefficients for several other solvents (55, 85, 87). In brief,
aliquots of olive oil, physiological saline or fresh human blood were added to
sample vials. Further, known amounts of MTBE, ETBE, TAME and TBA were
added both to sample vials and to reference vials. The reference vials were empty
except for inert glass pearls, which corresponded to the same volume as the liquid
in the sample vials (due to the pressure-injection method of the GC). The capped
vials were allowed to equilibrate at 37°C for at least 20 minutes, before head-
space GC analysis. The liquid/air partition coefficients were calculated from GC
peak areas, air (head space), and liquid volumes of the sample vials and the
reference vials.
Blood samples, obtained from five males and five females, were used to
calculated the inter individual variation (correlation of variance, CV) of the
λblood/air.
Liquid/air partition coefficients (Study IV) and tissue composition (12, 58, 131)
were used to calculate the tissue/blood partition coefficients needed in the PBTK
modeling (Study V).
λtissue/air=(% water content in tissue•λwater/air)+(% fat content in tissue•λfat/air)
4.5 Physiologically Based Toxicokinetic Modeling (Study V)
A PBTK model (Figure 7) was developed for inhalation exposure to ETBE using
the previously determined partition coefficients (study IV) and the experimental
data obtained in study II. To describe the kinetics of ETBE the following
compartments were used: lungs (including arterial blood), liver, fat, rapidly
perfused tissues (including kidney, brain and other tissues), resting muscles and
working muscles (to account for the leg exercise during bicycling, throughout the
exposure). The skin was included in the muscle compartments. The same set of
compartments and, in addition, a urinary excretion compartment were used for the
metabolite TBA. First order metabolism was assumed in the model, since linear
kinetics have been shown experimentally up to 50 ppm ETBE (Study II). Organ
volumes and blood flows were calculated from individual body weight and height
according to published equations (52) and the tissue/blood partition coefficients
were calculated as described in section 4.4.
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Figure 7. Physiologically based toxicokinetic model used in the simulations of ETBE
and the metabolite TBA.
A sensitivity analysis, according to Pierce et al. (132), was performed to
determine the influence of parameter values on blood, urine and exhaled air
levels.
Further, biomarker levels at the end of the workshift and the following morning
prior to the next workshift were predicted. The model was used to study how
various factors such as long-term exposure, fluctuations in exposure levels and
workload influenced the levels of biomarkers in blood, urine or exhaled air.
4.6 Acute Effects after MTBE and ETBE Exposures (Study VI
and VII)
Acute effects were measured, objectively and subjectively, in parallel with the
toxicokinetics during the same exposures. The battery of test for acute effects in
this study was extensive, laborious and, for some analyses, expensive. Therefore,
all subjects were first exposed to 50 ppm, whereas the following exposures to 5 or
25 ppm levels were random. End-points that did not result in any positive findings
at the highest exposure levels were excluded from the test battery during exposure
to the lower levels (see Table 5).
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Table 5. Acute effect tests performed under various exposure conditions (- indicates not
studied).
MTBE ETBE
Exposure levels (ppm) 5 25 50 0 5 25 50
Subjective ratings x x x x x x x
Ocular
Blinking frequency - - x - x x x
Eye redness - - x - - - x
Tearfilm stability - - x - - - x
Conjunctival epithelial damage - - x - x x x
Nasal
Blockage index x x x - - - -
Acoustic rhinometry x x - x x x x
Nasal lavage
Eosinophilic cationic protein - - x x x x x
Myeloperoxidase - - x x x x x
Lysozyme - - x x x x x
Albumin - - x x x x x
IL-8 - - - - - - x
Cell count - - x - - - x
Pulmonary
PEF x x x - x x x
Spirometry - - - x x x x
Transfer factor, diffusing capacity - - - x x x x
The subjects were informed about the experimental design, but were unaware
of the exposure level sequence. The 5 ppm level was chosen so the subjects could
smell the solvent in all exposures and thus not know the actual exposure level.
The original plan was that the level of 5 ppm would be the control condition, and
it was so in the MTBE study. However, some acute effects were observed at 5
ppm in the ETBE study and it was necessary to include a zero level (clean air)
exposure. The subjects were not informed that the last exposure was to be to clean
air.
4.6.1 Ratings of Symptoms
The subjects were asked to complete a questionnaire with 10 items related to
symptoms of irritation and effects on the central nervous system (discomfort in
the eyes, nose, throat and airways, difficulty in breathing, smell of solvent,
headache, fatigue, nausea, dizziness, intoxication). Answers were given by
marking with a pen along a 100 mm visual analog scale graded from “not at all”
to “almost unbearable” (Figure 8). During exposure, the ratings were performed
while exercising on the bicycle.
 
hardly
at all
not at all
somewhat rather quite very
almost unbearable
Figure 8.
 A visual analog scale (0-100 mm) used for ratings of various symptoms in a
questionnaire. All verbal grading and questions were written in Swedish.
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4.6.2 Ocular Measurements
Blinking Frequency
Blinking frequency was determined from video tape recordings where the number
of blinks was counted during 3 minutes at each occasion.
Eye Redness
The difference in eye redness was scored on a four-grade scale (94) by comparing
photographs (diapositives). The scorings were made in a blinded fashion, i.e.
without the observer knowing when the photo was taken.
Tearfilm Stability
Tearfilm stability was assessed in two ways. First, the self-reported break-up time
was monitored, i.e. the time the subject was able to keep his eyes open without
blinking (174). Second, the tearfilm stability was measured by observing the
tearfilm in a slitlamp microscope and recording the break-up time after instillation
of Fluorescein into the lower conjunctival sac (126). The tearfilm measurements
were performed in both eyes. The measurements at the end of the exposure were
performed at rest inside the chamber.
Conjunctival Epithelial Damage
Conjunctival epithelial damage was visualized by instilling a drop of Lissamine
Green into the lower conjunctival sac in the left eye. The eye was inspected in a
slitlamp microscope and the degree of corneal and conjunctival damage was
scored semi-quantitatively (126). To minimize interference the Lissamine Green
staining was performed after the other ocular measurements.
4.6.3 Nasal Measurements
Acoustic Rhinometry
The degree of swelling of the nasal mucosa was estimated by acoustic rhinometry
(63, 71). This method describes the geometry of the nasal cavity by analyzing the
reflections of an acoustic signal. The nasal volume, the minimal nasal cross-
sectional area and the minimal nasal diameter were determined as an average of
three measurements of each nostril.
Blockage Index
A peak expiratory flow (PEF) meter (measuring capacity 0 to 800 l/min) was
connected to a face mask to determine the nasal PEF. The subject exhaled
maximally into the flow meter through the nose with his mouth closed (mean of
three measurements). The blockage index, a measure of the nasal airway
resistance (153), was calculated as:
Blockage index = (pulmonary PEF - nasal PEF) / pulmonary PEF
(pulmonary PEF see section 4.6.4).
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Nasal Lavage
Nasal lavage was performed by rinsing each side of the nasal cavity with 5 ml of
sterile physiological saline (62). Leukocytes and epithelial cells were counted in
the nasal lavages and in addition, inflammatory markers (eosinophilic cationic
protein, myeloperoxidase, lysozyme, albumin and interleukin 8) were analyzed.
The levels of inflammatory markers were calculated and compared in two ways:
as the concentration and as the total amount in the recovered lavage fluid.
4.6.4 Pulmonary Measurements
Peak Expiratory Flow
The pulmonary PEF rate (average of three measurements) was performed by
blowing in a flow meter with a measuring range of 0 to 800 l/min (6).
Spirometry
Spirometry was carried out with a calibrated wedge spirometer (6). The subject
wore a nose clip and was asked to inhale as much as possible and thereafter
exhale completely in a mouthpiece. Three slow vital capacity (VC) maneuvers
were carried out followed by three forced vital capacity (FVC) exhalations. One
second forced expiratory volume (FEV1) was measured as the highest value of
three attempts and VC was measured as the maximum exhaled air from three slow
and three forced exhalations.
Transfer Factor
The transfer factor (TLco), which reflects the gas exchange characteristics of the
lung parenchyma, was measured with the single breath holding method (diffusing
capacity) using the Morgan Transfer test equipment (43). In brief, the subjects
inhaled a test gas consisting of 0.3% carbon monoxide (CO), 14% helium and
85.7% oxygen. The transfer factor (average of two measurements, TLco within
5%) was calculated from the rate of disappearance of CO from the alveolar gas
during a 10-sec breath holding period. The transfer of CO into the pulmonary
capillary is limited solely by diffusion and the concentrations is measured by an
infrared analyzer. Helium is added to the inspired gas to give a measurement of
lung volume by dilution.
4.7 Statistical Analysis
Unless otherwise stated, the results are presented as mean values with 95 %
confidence intervals. Student’s paired t-test was used to compare results from
different exposure occasions. Analysis of variance, repeated measures model, was
used to compare the subjective ratings and the acute effect measurements. The
level of significance was set to 0.05.
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5. Results and Discussion
5.1 Toxicokinetics of MTBE and ETBE (Studies I, II and III)
Results of uptake, excretion and clearance after exposure to 50 ppm MTBE,
ETBE and [1,2-13C2]-MTBE are presented in Table 6. Small differences in the
kinetics of the two oxygenates were found. MTBE had higher uptake and lower
respiratory excretion than ETBE. This was in agreement with the determined in
vitro partition coefficients (see section 5.3).
The concentration of parent ether in blood increased during the entire exposure
with a tendency to level off but without reaching any plateau (see Figure 9).
Similar concentration curves have been seen in other MTBE studies (33, 130,
135). A somewhat lower ETBE level in blood compared with MTBE was seen
and this was illustrated by a 15-30% lower blood AUC for ETBE, and is
explained by the lower uptake of ETBE (Table 6).
During these 2 h exposures no steady state (i.e. when the rate of uptake matches
the rate of elimination) was reached: neither for MTBE nor for ETBE.
Nonetheless, steady state concentrations could be calculated from the respiratory
uptake rate and the total blood clearance. For MTBE in blood the following
steady state concentrations were estimated: 2.3, 8.8 and 19 µM after the 5, 25 and
50 ppm MTBE exposure. After the 2 h exposure the following concentrations
were reached in blood: 1.3, 6.0 and 14 µM MTBE. The calculated steady state
levels in blood for ETBE were 1.5, 5.9 and 13 µM and the corresponding
measured levels after the 2 h exposure were 1.1, 5.4 and 10 µM ETBE, at 5, 25
and 50 ppm ETBE exposure, respectively.
Table 6.
 Results after whole-body exposure to 50 ppm MTBE (n=10) and 50 ppm ETBE
(n=8) and face-mask exposure to 50 ppm [1,2-13C2]-MTBE (n=4) during 2 h and at a
workload of 50 W (mean values ± 95% confidence interval).
MTBE ETBE [1,2-13C2]-MTBE
Parent ether
Respiratory uptake (%) 49 ± 10 34 ± 3 47 ± 7
Respiratory excretion (%) 32 ± 8 46 ± 5 29 ± 8
Urinary excretion (%) 0.09 ± 0.03 0.06 ± 0.02 0.1 ± 0.04
Total clearance (l/h/kg) 0.8 ± 0.2 0.8 ± 0.2 0.8 ±0.04
Exhalatory clearance (l/h/kg) 0.2 ± 0.08 0.4 ± 0.08 0.2 ± 0.07
Metabolic clearance (l/h/kg) 0.5 ± 0.1 0.4 ± 0.1 0.6 ± 0.05
Mean residence time (h) 6.1 ± 1.7 11 ± 7 4.0 ± 2.2
Metabolite, TBA
Respiratory excretion (%) nda 3.8 ± 0.9 2.0 ± 0.4
Urinary excretion (%) 0.6 ± 0.1 0.9 ± 0.5 0.6 ± 0.2
Renal clearance (ml/h/kg) 0.6 ± 0.1 1.0 ± 0.5 0.9 ± 0.4
a not determined
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Figure 9.
 A comparison of average concentration of MTBE and ETBE in blood after
MTBE (n=10) and ETBE (n=8) exposure.
The process of elimination of MTBE and ETBE from blood was separated into
four phases. The two fastest elimination phases had average half-times of 1 and
10 min and 2 and 18 min for MTBE and ETBE, respectively. The mean values
for the intermediate and the slowest phase were 1.5 and 19 h for MTBE and 1.7 h
and 28 h for ETBE. The half-times as well as the mean residence time (Table 6)
indicate a somewhat slower elimination of ETBE compared with MTBE.
The half-times of parent ether in urine were separated in two elimination
phases, with approximately 20 min and 3 h for MTBE and 8 min and 9 h for
ETBE. In agreement with the blood half-times, elimination of ETBE was slower
than elimination of MTBE.
In contrast to the parent ethers profile, TBA in blood increased steadily during
the exposure and remained high for several hours after TBA was eliminated
slowly from the body, as illustrated in Figure 9. About 4 h after the end of
exposure, TBA started to decline and the half-times of TBA in blood and in urine
were 8-12 h and 7.5-9 h, respectively.
Low urinary recovery of parent ether (<0.1%) and TBA (<1%) was seen after
all exposures (Table 6). This implies further metabolism or other excretion routes.
Further metabolism of MTBE has indeed been shown in humans, in Study III
(section 5.2) and in animals (17, 116). The excretion of minor amounts of
unchanged ETBE and MTBE in the urine was not a surprise, since these ethers
are only slightly water soluble. In fact, even less water-soluble chemicals e.g.,
styrene and trimethylbenzenes, are recovered in small amounts in human urine
(88, 127). Urinary excretion of small amounts of unmetabolized MTBE has been
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Figure 10.
 Comparison of average TBA levels in blood and urine after ether exposures.
demonstrated in two other experimental studies on volunteers (29, 130). The renal
clearance for TBA was low, less than 1 ml/kg/h, which implies extensive blood
protein binding or tubular reabsorption of TBA and makes a logical framework
for the possibility of further metabolism. The concentration of TBA in urine was
in general higher than the levels of TBA in blood (Figure 10). This could be
explained by the water/blood partition coefficient of TBA which was determined
to be 1.3 (study IV, Table 8), i.e. the level in urine should in average be 30%
higher than in blood. The water/blood partition coefficient is approximately equal
to the urine/blood partition coefficient, and this has been shown for MTBE (79).
The main excretion route for the unchanged ethers was via exhalation (Table
6), whereas a small amount TBA was also exhaled and detected in the ETBE
study. Approximately the same figures have been seen in other MTBE studies
(29, 130, 135). In total, less than 50% recovery (parent ethers and TBA) was
found in exhaled air and in urine within 24 h. However, taking into account the
quantification of the other metabolites (HBA and MPD) in the 20 h post exposure
urine sample, this indicates that a substantial amount is further metabolized and
excreted in the urine (section 5.2).
The area under the concentration-time curve (AUC) of parent ether and TBA in
blood was proportional against exposure levels. This illustrates linear kinetics up
to 50 ppm MTBE and ETBE.
The level of acetone (analyzed by GC) in blood (Figure 11) and in urine
increased during exposure and up to approximately two hours after the MTBE
and ETBE exposures (Studies II and III). In the ETBE-study, the average
concentration of acetone in blood (and AUC) was highest at the 50 ppm exposure,
but otherwise poorly related to the exposure levels. Acetone was detected in urine
as well. The highest cumulative urinary excretion was seen at the 50 ppm
29
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Figure 11.
 The concentration of acetone in blood after exposure to 0, 5, 25 and 50 ppm
ETBE. Mean levels and 95% confidence interval are given for eight subjects.
exposure level and the lowest at the control exposure; however, apart from this
there were no dose correlation of acetone. A wide inter individual variation in
acetone levels in blood and in urine was seen before, during and after the
exposure. This could probably be explained by the endogenous production of
acetone, since the acetone levels may change naturally through the day due to
e.g., physical exercise and food intake (86).
5.1.1 Whole-Body versus Face-Mask MTBE Exposure (Studies I and III)
The concentration curves for MTBE and TBA in blood after the face-mask
exposure (Study III) were similar to those obtained in the whole-body exposure
(Study I) (Figure 12). However, a somewhat higher dose was absorbed in the
face-mask study. The slight differences between these studies could be related to
e.g., the slight difference in analytical methods used in the two studies, continuos
versus intermittent breathing via valves respective measurement of pulmonary
ventilation, differences in exhalation based on breathing mask versus mouthpiece
and nose-clip, weight gain of about 2 kg for the participants over the past 3 years
and the breathing pattern. A statistically significant higher breathing frequency
was seen in the whole-body exposure compared with the face-mask exposure
study (Table 7). The subjects in the whole-body MTBE study were not used to
mouthpiece breathing and started to hyperventilate during the four exhalation
periods (5 minutes each) (Study I). During hyperventilation the alveolar
ventilation decreases and the dead space increases, relatively speaking (181). In
practice, this means that less MTBE was absorbed and the calculated absorbed
dose in the whole-body exposure (Study I) was then probably underestimated
since the estimations were based on the mouthpiece exhalations during exposure.
However, it could be assumed that the volunteers had normal breathing frequency
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Figure 12. Comparison between the whole-body MTBE exposure (Study I) and face-
mask [1,2-13C2]-MTBE exposure (Study III). Mean values of MTBE and TBA in blood
from four subjects exposed to 50 ppm MTBE are given.
during the rest of the exposure, since the concentration curves of MTBE in blood
match so well in the two different exposure studies (Figure 12).
The breathing frequency measured during the four exhalation periods (5
minutes each) in the ETBE study did not differ from the [1,2-13C2]-MTBE
breathing frequency measured during the entire exposure, even though different
subjects participated in the two studies.
In conclusion, the absence of major differences in the toxicokinetics implies
that dermal uptake does not contribute significantly to the total uptake of MTBE
during the whole-body exposure.
Table 7.
 Pulmonary ventilation and breathing frequency during and after whole-body
exposure to 50 ppm MTBE and 50 ppm ETBE and face-mask exposure to 50 ppm
[1,2-13C2]-MTBE are given (mean values ± 95% confidence interval). During the 2 h
exposure the subjects performed physical exercise (50 W) on ergometer bicycles.
MTBE
(n=10)
ETBE
(n=8)
[1,2-13C2]-MTBE
(n=4)
MTBE a
(n=4)
During exposure
Pulmonary ventilation (l/min) 23 ± 3.3 b 24 ± 0.9 b 23 ± 2.4 c 25 ± 2.1 b
Breathing frequency (breaths/min) 22 ± 2.0 b 18 ± 1.2 b 18 ± 3.5 c 24 ± 3.5 b
After exposure
Pulmonary ventilation (l/min) 12 ± 1.5 11 ± 0.7 12 ± 2.4 10 ± 1.3
Breathing frequency (breaths/min) 17 ± 2.2 15 ± 1.2 15 ± 2.4 19 ± 5.0
a
 Results from the same four subjects in the unlabeled MTBE exposure (Study I) as in the
[1,2-13C2]-MTBE exposure (Study III).
b
 Average of approximately 20 min of exhalation via mouthpiece during whole-body exposure.
c
 Average of all exhalations during the entire 2-h face-mask exposure.
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5.2 Urinary Metabolites after [1,2-13C2]-MTBE Exposure (Study III)
5.2.1 Characterization
In this study, signals from the 13C-labeled portion of [1,2-13C2]-MTBE and derived
metabolites should arise in doublet patterns (two adjacent 13C-nuclei) enabling the
distinction from endogenous compounds (singlet patterns). Chemical shifts for the
13C-labeled portion of the urinary metabolites were consistent with the shifts
obtained for spiked standards of HBA and MPD, see Figures 13 and 14. NMR
signals were not detected for labeled MTBE, TBA, or possible MTBE-derived
glucuronide conjugates, probably due to insufficient sensitivity.
In a previous study, rats were exposed for 6 h to 2000 ppm [2-13C]-MTBE and a
human consumed 400 mg of [2-13C]-TBA (17). TBA-conjugates (glucuronide and
sulfate) and an unknown metabolite in urine were attributed to [2-13C]-MTBE. In
the present study, a number of signals were observed in those spectral regions
both in the control urine and in urine from MTBE exposed humans. These signals
could not be defined as doublets. However, singlets in these regions could arise
from [1,2-13C2]-MTBE metabolites that may possess only one labeled carbon, such
as acetone and metabolites formed from acetone, e.g., 1,2-propanediol and lactate
(Figure 2) or from endogenous compounds that are excreted at different
concentrations throughout the day. Conjugates of e.g., TBA and MPD, on the
other hand, should give rise to doublets in the present study, since they would
contain two labeled carbons from [1,2-13C2]-MTBE. In the previous study (17),
the administered MTBE or TBA was labeled only at the carbon 2-position,
prohibiting the use of carbon-carbon coupling patterns to confirm that the
assigned singlets were derived from labeled MTBE or TBA. In another previous
study, conjugates from [1,2,3-13C3]-TAME have been assigned in urine obtained
from rats and mice administered (152). In the present study, it was possible that
MTBE-derived glucuronide and sulfate conjugates did exist in the urine but below
the detection limit of the NMR method. In addition, given that the ratio of
HBA:MPD increases with time after termination of exposure, it was also possible
that conjugates would form to a greater extent after 20 h post exposure, which
was the time point when the last urine sample was taken.
5.2.2 Quantification
Quantification of MPD and HBA was performed by NMR in two urine samples
(collected 20 h post exposure from two volunteers) that had sufficient amounts of
metabolites to quantify. Previously only one metabolite, TBA, has been identified
in human urine and with a low recovery (<1%) (Study I). In study III, the two
urine samples contained 1% MPD (0.12 mM) and 11% HBA (0.96 mM) (urine
diluted in D2O) or 1% MPD (0.06 mM) and 3% HBA (0.17 mM) (concentrated
urine after protein precipitation). The percentage values are expressed as
percentage of MTBE uptake. This indicates that HBA and MPD occur at
markedly higher levels in the urine (detected by NMR) than MTBE and TBA
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Figure 14.
 Metabolites of [1,2-13C2]-MTBE shown in study III (*; 13C-labeled carbons).
5.3 Partition Coefficients (Study IV)
The partition coefficients illustrate that MTBE, ETBE and TAME have higher
affinity to adipose tissue than to blood, as do many other solvents. Further, the
partition coefficients implies that ETBE would have the lowest respiratory uptake
of these ethers and that TAME might have longer half-times since it accumulates
for a longer time in adipose tissue. The low oil/water and oil/blood values for
TBA indicate that TBA was preferentially distributed in the body water. Average
values for measured liquid/air partition coefficients and calculated tissue/blood
partition coefficients are given in Table 8. The present partition coefficients agree
rather well with partition coefficients for MTBE obtained from blood and tissues
in rats (25, 133), from oil/nitrogen (32), and from a recent study (79) of human
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Table 8.
 Measured liquid/air partition coefficients (Study IV) of oxygenates and a
metabolite in blood, watera and oil (average values of 25 samples are given) and in
addition, calculated tissue/blood partition coefficients are given.
Measured Calculatedb
Partition
coefficients
blood
air
water a
air
oil
air
water a
blood
fat
blood
liver
blood
muscle
blood
rpt c
blood
MTBE 18 15 120 0.86 5.3 1.1 1.1 1.4
ETBE 12 8.4 190 0.72 12 1.7 1.7 2.3
TAME 18 12 340 0.66 14 1.8 1.9 2.6
TBA 460 600 170 1.3 0.57 1.0 1.0 1.0
a
 Strictly physiological saline
b
 Calculated from tissue composition (percentage water and oil content) (12, 58, 131) and
measured liquid/air partition coefficients in vitro (Study IV).
c
 Partition coefficient of the rapidly perfused tissues/blood (rpt/blood) calculated from tissue
composition (percentage water and oil content) of the brain (58) and measured liquid/air
partition coefficients in vitro (Study IV).
blood/air, urine/air, saline/air and oil/air partition coefficients (λ: 20, 16, 15, and
140, respectively).
Further, inter individual variation (CV) of the λblood/air
 
(10 subjects) was
calculated and estimated to 14% for MTBE, 20% for ETBE, 20% for TAME and
30% for TBA. These coefficients of variation are in agreement with previously
reported CV of other compounds (7.3, 13, 16 and 16% respectively for acetone,
1,1,1-trichloroethane, toluene and styrene) determined from 73 subjects (20
analyses per individual) (49). In the present study as well as in the previously
mentioned study, sex was not seen to be a significant grouping variable for the
individual blood/air partition coefficients.
5.4 Physiologically Based Toxicokinetic Modeling (Study V)
The model could adequately describe the experimental data (Figure 15). The
sensitivity of the model towards different parameters was studied by sensitivity
analysis. The parameters that influenced the levels of ETBE in blood and exhaled
air were mainly alveolar ventilation, the blood/air partition coefficient of ETBE,
and parameters associated with fat, such as body weight. The sensitivity analysis
indicated that parameters having the largest influence on TBA levels in blood and
exhaled air were associated with the liver, the blood/air and liver/blood partition
coefficients for ETBE and TBA. Further, the sensitivity coefficients illustrate that
parameters have a complex time-dependent behavior.
Predicted levels in venous blood and in fat tissue after two weeks of exposure at
50 ppm ETBE (8 h a day for 5 consecutive days) are shown in Figure 16. Only
slightly increased biomarker levels (in blood, exhaled air and urine) were seen at
the end of the workshift and the following morning (day 2 to day 5). ETBE, and
to a lesser degree TBA, accumulated slightly in fat tissue after weeks of exposure
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Figure 15. Experimental (dots) (Study II) and predicted values (lines) for one individual
after exposure to 5, 25 and 50 ppm ETBE for 2 h at 50 W. Symbols; { - ETBE in blood
(µM),  - ETBE in exhaled air (µmol/min), z - TBA in blood (µM),  - TBA in exhaled
air (µmol/min), and  - urinary excretion rate of TBA (µmol/min).
at 50 ppm ETBE. According to the model, workload (0 to 100 W) increases all
biomarker levels by approximately 2-fold at the end of the workshift, and by 3-
fold the next morning. This illustrates that biological exposure monitoring is very
important, because the internal exposure might be strongly underestimated by air
monitoring if physically demanding work tasks are performed. The effect of
workload depends on the blood/air partition coefficients, alveolar ventilation,
cardiac output and distribution in a complex manner.
Table 9. Results from 500 Monte Carlo simulations of random fluctuating exposure to
50 ppm ETBE at 50W. Scenario 1 illustrates continuous ETBE emission with rapid air
exchange and scenario 2 intermittent emission with slow air exchange. The coefficients
of variation (CV) in biomarker levels are given for ETBE and its metabolite, TBA, at the
end of an 8 h shift and the next morning prior to next shift (16 h post exposure).
ETBE TBA
CV (%) Venous
blood
Exhaled
air
Venous
blood
Exhaled
air
Urinea Urineb
Scenario 1
End of workshift     4.4 17     0.8     0.7     1.9     0.7
Next morning     1.1     1.1     1.0     1.0     1.6     1.0
Scenario 2
End of workshift 44 84     6.8     7.3     7.4     7.2
Next morning 13 13 11 11 12 11
a
 variability in urinary excretion rate levels
b
 variability in urinary concentration levels
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Figure 16. Predicted levels of ETBE and TBA in blood, exhaled air, urine and fat tissue
after two weeks (8 h/day, 8 AM to noon and 1 PM to 5 PM, 5 consecutive days) of
exposure to 50 ppm ETBE and at a workload of 50W. The workload was set to zero at
night (11 PM to 7 AM), whereas light physical activity (25 W) was assumed for the
remaining time.
Fluctuations in an 8 h exposure were estimated with 500 Monte Carlo
simulations. These simulations shows that ETBE in blood and exhaled air at the
end of the workshift was highly sensitive to exposure fluctuations, whereas ETBE
next morning and TBA in general was less sensitive to fluctuations (Table 9).
Predicted inter individual variability (eight subjects) in biomarker levels is
higher the next morning than at the end of the workshift, and higher for TBA than
for ETBE (Table 10). Further, a rather high variability of biomarker levels was
seen on Monday morning after one working week of exposure (37-48% for ETBE
and 49-58% for TBA).
Table 10.
 The variability (coefficient of variation, CV) between eight individuals
simulated levels of ETBE and TBA in blood, exhaled air and urine after exposure to 50
ppm ETBE (50 W) 8 h daily for five consecutive days (end of workshift = average CV
Monday to Friday; next morning = average CV Tuesday to Saturday).
ETBE TBA
CV (%) Venous blood Exhaled air Venous blood Exhaled air Urinea Urineb
End of shift 7.1 4.2 9.6 8.5 44 9.5
Next morning 7.6 9.1 20 20 39 21
a
 variability in urinary excretion rate levels
b
 variability in urinary concentration levels
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5.5 Acute Effects after MTBE and ETBE Exposures (Studies VI
and VII)
The ratings of solvent smell increased dramatically in the beginning of the
exposure and then gradually decreased during exposure (MTBE and ETBE).
Further, the solvent smell ratings were related to exposure levels, illustrating the
potential of the questionnaire to pick up feelings of discomfort. No significant
ratings (except solvent smell) were seen regarding the other questions in the
MTBE study. However, in the ETBE study, significantly elevated ratings of
discomfort in throat and airways were seen at 50 ppm ETBE compared to the
clean air level. Further, the average ratings for the other questions corresponded
verbally to something between “not at all” and “hardly at all”, i.e. in the range of
0-10 mm on the visual analog scale. The questionnaire was elaborated for solvent
exposure and has been used in several similar inhalation studies at our laboratory
(56, 82, 88). The scale was originally developed and validated for measuring
annoyance from noise (95).
All eye measurements were negative after the MTBE exposure and in the
majority of the ocular tests in the ETBE study. But an increase in blinking
frequency, from on average 10 blinks per min before exposure to 14 blinks per
min during exposure was seen in the ETBE study. Still, this effect did not
correlate with exposure levels.
Nasal swelling, expressed as a 6-15% decrease in the nasal volume measured
by acoustic rhinometry, was observed at all exposure levels in the ETBE study. A
nasal swelling effect was also seen in the MTBE study. However, neither in the
ETBE nor in the MTBE study did this effect correlate to exposure levels and no
significant increases in cell count or in biochemical inflammatory markers were
seen in the nasal lavage fluid.
Since the nasal swelling and the blinking frequency did not correlate with the
exposure level, these effects may be related to other factors than ETBE. Plausible
explanations might be e.g. bicycle exercise, possible daily variation or slightly
different climate in the chamber.
Pulmonary effects were measured in the ETBE study but not in the MTBE
study. Impaired lung function, expressed as reductions in vital capacity and forced
vital capacity (significant), FEV1 (not significant) and TLco (of borderline
significance), was noted at the two highest exposure levels (25 and 50 ppm)
compared with the lower ones (0 and 5 ppm). These impairments seemed to fall
within the normal inter and intra individual variability and presumably have no
clinical relevance as such. However, it cannot be excluded that other subjects,
maybe more sensitive ones, may react more strongly or that a longer exposure
duration might give a more pronounced effect.
The acute effects in volunteers after controlled experimental exposure to MTBE
and ETBE are summarized in Table 11.
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Table 11.
 Comparison of acute effects in man after controlled experimental exposure (2
h, 50 W) to MTBE (n=10) and ETBE (n=8).
Effect measure MTBE ETBE
Effect versus exposure level and time
Rating of smell ↑ ↑
Rating of discomfort in throat and airways ↔ ↑
Vital capacity nd ↓
Forced vital capacity nd ↓
Effect versus time
FEV1 (forced expiratory volume in 1 sec) nd ↓
TLco (transfer factor of diffusing capacity) nd ↓
Blinking frequency ↔ ↑
Nasal swelling ↑ ↑
Albumin in nasal lavage ↓ ↓
Myeloperoxidase in nasal lavage ↓ ↔
Interleukin 8 in nasal lavage nd ↓
↑ : Increased significantly (p<0.05, repeated measures ANOVA)
↓ : Decreased significantly (p<0.05, repeated measures ANOVA)
↔ : No significant effect (p>0.05, repeated measures ANOVA)
nd: Not determined
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6. General Discussion
6.1 Measures of Exposure
Paracelsus pointed out half a millennium ago: “All substances are poisons, there
is none which is not a poison. The right dose differentiates a poison from a
remedy” (4). In toxicology, it is essential to establish the dose-response (the
proportion of a population showing a specified change) and dose-effect (the
magnitude of change in a parameter).
A dose, or the amount of xenobiotics entering the body, can be expressed as
exposure dose (in the case the concentration measured in air), absorbed dose
(internal dose or body burden), tissue dose or target tissue dose (the dose in tissue
relevant for the adverse effect). Air concentration is measured by air monitoring,
and body burden by biological monitoring. Tissue doses in humans are usually
predicted, e.g. using a PBTK model.
6.1.1 Biological monitoring
The definition of biological exposure monitoring in the occupational health field
is “the measurement and assessment of workplace agents or their metabolites
either in tissues, secreta, excreta, expired air or any combination of these to
evaluate exposure and health risk compared with an appropriate reference” (172).
The chemical, or a metabolite, is usually assayed from blood, urine and exhaled
air. Saliva, fat, milk, hair, nails or tissue biopsies are more rarely used.
Urine samples are the most commonly used body fluid in biological exposure
monitoring mainly because of the practical and non-invasive sampling technique.
When a metabolite is monitored, urine levels are much less influenced by peak
exposures than the concentration of the unchanged chemical in blood or exhaled
air. The time of urine collection and the urine output are the most influential
factors for the urine concentration. Urine output changes with e.g., water intake,
surrounding temperature, humidity and physical activity. However, the urinary
output is not influencing that much if the urinary excretion rate of a chemical is
reported, instead of the concentration. In order to exclude over-diluted or over-
concentrated samples it is sometimes advisable to relate the urine concentration to
the endogenous urinary creatinine levels or urine density (22, 72). In controlled
experimental exposures, as in the present thesis, all urine produced during one day
is usually collected. Therefore, the urinary excretion rate can be calculated and
the correction for dilution is not necessary.
Blood samples are primarily used when the exposure is too low for a detectable
amount of chemical or metabolite in urine analysis. The determination of
unchanged chemical in blood usually has higher specificity compared to that of a
metabolite which may originate from several other substances. The concentration
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in blood or alveolar air frequently has the same significance, i.e. it reflects the
most recent exposure (sampling during or at the end of the workshift) or the
integrated exposure (sampling next morning).
In the present studies, capillary blood samples were analyzed. Capillary blood
mainly represents arterial blood. A direct comparison to venous blood levels is
not possible, since the pulmonary uptake or wash-out of volatile chemicals creates
a difference between arterial and venous blood. Further, sampling venous blood
from body parts that have been in direct contact with a chemical may result in
inaccurate concentrations because of dermal absorption. In the present studies the
subjects washed their hand in water before we took a capillary blood sample.
For levels in exhaled air, the most important factor is the affinity to blood - the
blood/air partition coefficient. A chemical less soluble in blood will show higher
concentration in exhaled air (lower uptake). In general, chemicals that are less
soluble in blood and/or are eliminated mainly unchanged in the lung, are the most
suitable for use as biomarkers in exhaled air. These criteria are met by the parent
ethers in this study. The time of sampling exhaled air is very critical. Exhaled air
can be sampled as mixed-exhaled air or as end-exhaled air. The former represents
the gas mixture displaced from the dead space and from alveoli. Mixed-exhaled
air was collected in the present exposure studies.
When a monitoring method is based on the determination of a chemical or its
metabolite in biological media, it is essential to know the toxicokinetics (further
discussed in Section 6.2), i.e. how the substance is absorbed (lung, gastrointestinal
tract and skin), distributed to different compartments in the body, biotransformed
and finally excreted. The rate of uptake depends on the affinity of a chemical for
the tissues and on the tissue perfusion rate. For many chemicals, the concentration
in alveolar air and in blood increases rapidly during exposure, after which the
chemical is eliminated very quickly, as illustrated in Figures 9 and 12 for the
unmetabolized ethers. It is also important to know if the chemical will accumulate
in the body. For example, levels of TBA in blood and of the parent ethers in e.g.
adipose tissue, build up slowly and are eliminated at a lower rate. If the exposure
is intermittent, measurements of the concentrations in blood and exhaled air are of
little value during exposure, whereas at the end of exposure, smooth elimination
curves are observed. The different kinetic aspects of the unchanged compound
and the metabolite must be considered when choosing the time of sampling. If the
biological half-time is not too short (> 2 h) (172), the sampling after the work
shift or next morning may provide a reliable picture of the exposure during the
preceding shift. When the half-time is so short that the timing cannot be
controlled in field conditions, biological monitoring is unsuitable (59). This is
usually the case when monitoring solvents in exhaled air collected during the first
hour post exposure (exemplified by the present ethers). Further, some substances
may have several half-times corresponding to the elimination from different
organs or tissues, as illustrated with the unmetabolized ethers. Other chemicals or
metabolites have a relatively slow monoexponential decay and, hence, the time of
sampling is then less crucial, as illustrated for TBA in blood and urine. Further,
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the concentration of the substance is of importance, since higher levels often
mean less analytical variability and make the detection limit of the method less
important. Furthermore, the volatility is important, since volatile substances are
sensitive to sampling procedures. If the concentration the next morning has not
returned to the pre-shift level, a progressive accumulation during a week of
exposure is to be expected and the longer the half-time, the larger the contribution
of previous exposure (59).
6.1.2 Complexities
Several inter individual variables affect the uptake and metabolism of a chemical,
e.g. (4, 72, 106, 144, 169):
• pulmonary ventilation: respiratory rate, fitness and exercise,
• body composition: obese - lean or pregnant,
• work practices: route of exposure, fluctuations of exposure intensity, coexposure
to other chemicals, temperature and humidity during exposure,
• partitioning between air/blood and blood/fat,
• addiction / aversion to the solvent,
• inter individual variation in metabolic clearance rates: genetic variability in
biotransformation including genetic polymorphism,
• age, sex and ethnicity,
• confounding factors due to individual life style e.g., drugs, disease, alcohol,
smoking, diet, after work activities and exposure, personal hygiene, working and
eating habits.
A better understanding of individual factors is needed to improve risk
assessments and biological monitoring.
In the experimental exposure studies in the present thesis, some affecting
factors have been standardized. For example, the volunteers were all healthy
Caucasian males (20-50 years) and they had to refrain from alcohol and drugs
before and during the exposures. Further, the dose, route of exposure, workload
and the climate were standardized and the pulmonary ventilation was measured.
Diet, genetic variability or variation in partition coefficients are other factors that
may vary between subjects and this was not accounted for in the present
controlled exposures. Not all of these factors can be controlled in fields studies
and, e.g., an increased physical activity will most probably result in an increased
body burden as illustrated earlier in the PBTK predictions (section 5.4). The
effect of exercise is more pronounced for highly blood-soluble compounds (58).
Further, if an exposure period is short, the results may not be representative for
exposure during longer periods due to saturable metabolism, cofactor depletion,
enzyme induction or inhibition.
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6.1.3 Ethers and their Metabolites as Biomarkers
There may be both advantages and disadvantages to use the unmetabolized ethers
and TBA, respectively, as biological exposure markers for gasoline vapor. For
example, TBA may be a more suitable biomarker compared to the ethers for the
following practical and toxicokinetic reasons:
• TBA is cleared more slowly from the body compared to the parent ether, i.e.
timing is not crucial for TBA. In blood, TBA has a plateau several hours post
exposure and thereafter one linear single elimination phase was seen in blood
and urine (MTBE and ETBE have several elimination phases) (Studies I and II).
• TBA is found to be less sensitive to fluctuations in the exposure air levels
compared to the parent ether, especially at the end of the workshift (Study V).
• TBA has a higher recovery in the urine compared to unmetabolized ethers
(Studies I and II), i.e. less analytical limitations.
• TBA is less volatile, i.e. less sensitive to sample losses, than the parent ethers.
For reasons discussed previously (section 6.1.1) sampling of urine is preferable
to sampling of blood or exhaled air. In the PBTK predictions using ETBE data
from 8 subjects (Table 10) a higher variability is seen for TBA in urine compared
with TBA in blood or exhaled air (Study V). However, this is seen only for the
urinary excretion rate and not the urinary concentration of TBA (Figure 17 and
Table 10). Therefore the urinary concentration of TBA is most likely preferred to
excretion rate in biological monitoring. For other small molecules e.g., acetone
and methanol ACGIH has recommended to measure urinary concentration (5). In
the present studies, data on the unmetabolized ether and TBA have been analyzed
and used in the PBTK predictions. Two other urinary metabolites have recently
been characterized and excreted in higher amounts than TBA (Study III). These
two metabolites, HBA and MPD, may be even more suitable as biomarkers for
the oxygenates and gasoline vapor.
A potential drawback against the use of TBA (or metabolites of TBA) as a
biomarker of ether and gasoline is that TBA itself might also be present in the
environment (154). First, TBA may be present in commercial oxygenate liquid as
was the case in the ETBE study (0.4% TBA). Second, TBA may be added as an
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Figure 17. Average coefficient of variation (CV) for TBA in urine is given for urinary
concentration (µM) and excretion rate (µmol/h) after 50 ppm and 25 ppm MTBE (n=10)
and ETBE (n=8) exposures.
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oxygenate to gasoline. A third possibility is that TBA is used for other purposes,
e.g., as an industrial solvent (dehydrating agent, denaturant in ethanol and other
alcohols, and in extraction processes) (143, 154).
If there is reason to suspect exposure to TBA then the unmetabolized ethers
may be considered as biomarkers. Venous blood samples are preferable to urine
and exhaled air samples. This is because the low urinary recovery, risk of losses
due to the volatile ether, and that e.g. physical activity increases the excretion of
the ethers through the exhaled air. The timing is crucial for the unchanged ethers
due to the fast decay and the multiple elimination phases. The PBTK simulations
of ETBE (Study V) illustrates that it is more appropriate i.e. lower variability
(Table 9), to measure the unmetabolized ether the following morning prior to the
next shift compared to at the end of the workshift. The former alternative is more
insensitive to timing, but may suffer from e.g., analytical limitations.
6.2 Toxicokinetics
Three main factors determine the uptake, distribution and elimination of inhaled
vapors and gases:
• the rate by which the vapor is transferred from the environment to the tissue and
vice versa (mainly affected by cardiac output, blood/air partition coefficients,
alveolar ventilation),
• the capacity of the body to retain the inhaled substance and
• excretion and metabolism.
The uptake (absorption) in occupational settings is usually via inhalation or
through the skin and large surface areas are exposed in both cases.
In the two present MTBE studies, the same subjects were exposed to MTBE
vapor both whole-body (Study I) and via face-mask (Study III). Theoretically,
both respiratory and dermal absorption might take place in Study I. However,
after the face-mask study we could conclude that due to the absence of major
differences in the toxicokinetics, it is plausible that dermal uptake does not
contribute significantly to the total uptake during whole-body exposure to MTBE
vapor.
The solubility of compounds plays an essential role in the uptake, distribution
and elimination. The in vitro determined blood/air partition coefficients reflect
both the solubility and the binding to the red blood cell (hemoglobin) and plasma
proteins (97). The blood/air partition coefficients for the oxygenates and TBA
were determined in a wide concentration range and no saturable binding was seen.
Xenobiotics are distributed via the blood circulation from the site of absorption
to various tissues. The uptake rate of a compound may be limited either by
diffusion or blood flow (perfusion). If the diffusion of a chemical across
membranes is slow, the rate of entry into the tissues is limited. Conversely, if
diffusion across membranes is rapid, the rate of entry is limited by the rate of
delivery, i.e. perfusion rate limitation. Highly water soluble compounds (such as
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phase II conjugates) are generally diffusion rate limited, whereas blood flow
limitation applies more often to lipid-soluble compounds in slowly perfused
systems such as adipose tissues. Small molecules like the ethers are assumed to
diffuse rapidly across the membranes and blood flow may be the rate limiting
step. Hence, the PBTK model was perfusion-limited (Study V).
The main elimination processes by which the circulating levels of a compound
are irreversibly reduced are biotransformation (metabolism) and excretion.
Generally, biotransformation leads to generation of hydrophilic substances that
are readily excreted. The elimination is usually in urine, but excretion may also be
e.g. via the lungs or feces. Metabolism usually results in a detoxification of the
compound, but the reverse may also happen and more reactive intermediates may
be formed.
For the ethers dealt with here it is not known whether it is the unmetabolized
ethers or metabolites, such as formaldehyde, acetaldehyde, TBA or other
metabolites, that make the oxygenates “toxic” in animals at high levels. For
substances lacking functional groups, like MTBE or ETBE, an initial oxidation
step (phase I) is required before conjugation (phase II) to more water soluble
products can occur. MTBE activates P450 isoenzymes (phase I metabolism) and
the UDP-glucuronosyltransferase (phase II - conjugates) in liver microsomes from
both man and rats (26, 74, 147, 158), and it has been shown that extrahepatic
metabolism occurs in microsomes obtained from rats (73). In the present studies
low levels of TBA were found in the exhaled air after the ETBE and [1,2-13C2]-
MTBE exposures. Pekari et al. (130) have also reported negligible amounts of
TBA in the exhaled air after MTBE exposure.
Metabolic clearance of MTBE and ETBE was moderate and presumably
limited by both perfusion and enzymatic capacity. No steady state was achieved
after these 2-h exposures. This could be explained by the relatively high blood/air
partition coefficient and the low metabolic rate. The latter in combination with the
large blood flow through the lungs explains the relative importance of the
exhalation as elimination route for the ethers. For MTBE (Study I), however, the
levels in exhaled air may be somewhat overestimated and consequently the
adsorbed dose underestimated due to hyperventilation during exposure (section
5.1.1).
6.3 Modeling of Kinetic Data
PBTK models have an essential advantage compared to traditional computer
models, since the aim of PBTK models is to describe events in the entire body.
However, like all models, PBTK models are simplifications of reality that help us
to predict the elapse of a chemical in tissues in the body.
In the present PBTK model (Study V), the partition coefficients used are group
averages and not individual estimates, since it has been shown that most subjects
can be represented by group averages (49). Body build (described by body height
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and body weight) influenced the tissue volumes and the blood flow used in the
PBTK model (52) and, in addition, the blood flow was influenced by physical
exercise. Individual exposure duration, workload, body weight and body height
were used as individual input values in the model. Two muscle compartments,
one resting and one working, were used in the model in order to account for
physical exercise (bicycling, increasing blood flow in the legs) during exposure
(Study II) and indeed the model had an overall good fit to the experimentally
collected data. Further, workload was set to 25 W post exposure instead of the
commonly used 0 W. The former is probably a more correct estimate of physical
exercise during the leisure time.
Linear kinetics was seen up to 50 ppm MTBE (Study I) (75 ppm MTBE in
another study (130)), up to 50 ppm ETBE (Study II) in humans and in addition,
up to 300 ppm MTBE in animals (147). Deviations from linearity have been seen
at high doses in animals, e.g. at 8000 ppm or 400 mg/kg MTBE (116) and at 5000
ppm ETBE (23). Linear kinetics was assumed in the present PBTK model, since
no saturation has been seen up to 50 ppm ETBE in humans. This exposure level is
very high compared to observed occupational and non-occupational levels of
MTBE (see Table 2) (64, 69). This makes the assumption of first order kinetics
plausible, and the model should be adequate for most exposure situations.
Further, in this PBTK model, metabolism was postulated to exist only in the
liver. This is probably a simplification, since TBA has been measured in vitro in
extrahepatic microsomes obtained from rats (73). In the PBTK model, TBA was
excreted both from the lungs and via the urine. The uptake of TBA was due to the
contamination of the ETBE liquid (0.4% TBA) in the experimental study and also
to the fact that the metabolite TBA was probably excreted through the lungs too.
The latter we found plausible since the pulmonary excretion of TBA was higher
than the TBA exposure levels (Study II).
6.4 Acute Effects
With the battery of tests for acute effects in Studies VI and VII we tried to
examine acute effects, since complaints (e.g. headache, irritation and nausea)
appear to have emerged after the addition of MTBE to gasoline (described in
section 3.5) (69, 120, 166).
6.4.1 Oxygenates
The chosen acute effect test battery has been used in other MTBE exposure
studies (33, 135) and in previous chamber exposures at our department (44, 56,
82). Although some of the end points in the acute effect battery have not been
thoroughly validated, the tests have nonetheless been used and effects have been
seen in several field and experimental studies (60, 93, 96, 125, 129, 162, 180).
Statistically significant increases in ratings of smell were seen during and after
the exposures, and in addition the ratings correlated well to exposure levels. In the
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MTBE study (Study VI) no question, except smell, showed any significant
elevated ratings, whereas significantly elevated ratings of discomfort in throat and
airways were seen after the 50 ppm ETBE exposure compared to the control
exposure. Most of the remaining questions in the ETBE study were in average
rated highest at the 50 ppm ETBE exposure, but no such trend was seen for
MTBE. The ratings were in generally low, nevertheless, single subjects might
have rated up to "somewhat" (30% of the scale) at some occasion during the 50
ppm exposure. Further, after the two highest ETBE exposures, some of the
participants reported a bad taste in their mouth and the taste lasted for more than
one day post exposure. This was not mentioned or noticed after the MTBE
exposures, but it is possible that it have been oversighted in the previous study.
Nevertheless, this finding may partly be explained by the more annoying smell of
ETBE, the lower odor detection threshold for ETBE (69, 160), and of the smell of
possible exhaled metabolites or contaminants.
Nasal swelling, e.g., is a commonly reported symptom during exposure to
airborne substances. Nasal swelling has been previously seen in woodworking
teachers exposed mainly to wood dust (180) and in healthy volunteers exposed to
volatile organic compounds (125). Further, the biochemical markers analyzed in
nasal lavage are indicators of early nasal inflammation. Increasing levels of
albumin and eosinophilic cationic protein have previously been seen after
formaldehyde, nitrogen dioxide and ozone exposure (96, 129, 162). In a recent
study, a correlation between nasal swelling (measured by acoustic rhinometry)
and biomarkers in nasal lavage (ECP and lysozyme) has been seen in personnel
working in schools with a low air exchange rate (175). In the present studies
(Studies VI and VII), nasal swelling was indeed seen; however, it seems unlikely
that the effect is related to the ether exposure since there was no dose-effect
correlation. Other exposure-related factors, such as bicycling, or climate change
or daily variation may have influenced the observed effect.
Ocular measurements have previously given positive findings, e.g., eye redness
is found among tobacco workers (93) and reduced break-up time and increased
Lissamine green staining is seen in office workers due to indoor climate problems
(60). In the present studies, no ocular effects were seen after the MTBE or ETBE
exposures apart from an increased blinking frequency (without a dose-effect
relationship) that was seen after the ETBE exposures.
Impaired lung function was noted at the two highest ETBE exposure levels (25
and 50 ppm) compared to the control exposure, suggesting an ETBE-related
effect in these healthy volunteers. Several different pulmonary measures point in
the same direction and a small but significant impairment is shown in Study VII.
Still, it may be the case that in sensitive individuals, a prolonged or repeated
exposure to ETBE could cause a more pronounced effect. Unfortunately,
pulmonary function was not assessed in the MTBE study; therefore comparisons
between the two ethers cannot be made in this respect.
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6.4.2 Gasoline
The acute health effects reported after exposure to gasoline containing MTBE, are
in most cases similar to the effects of exposure to other constituents of gasoline
and emissions from motor vehicles (35, 139). Irritation in the eyes and respiratory
tract gives the first signs of toxic effects of gasoline, whereas higher
concentrations affect the central nervous system and e.g., headache, nausea,
dizziness and ataxia have been reported (168). Associations between gasoline
exposure and renal and liver cancer (seen in some studies and not in others (80)),
acute myeloid leukemia (101), changes in CNS (31), skin alterations and
modifications of the mucous membranes (105) have been reported in some
epidemiological studies (35).
Several decades ago, volunteers were experimentally exposed to gasoline vapor
(51). In an 8 h controlled exposure study, thirteen men were exposed to up to 270
ppm and eight women to up to 160 ppm gasoline vapor. The most distinctive
symptoms were irritation of the eyes and the throat. Further, after exposure for up
to five minutes at higher concentrations (up to 11000 ppm) the subjects felt
intoxicated (dizziness, incoordination and drunkenness), i.e. CNS symptoms. The
authors nonetheless concluded that commercial gasoline - as formulated in 1943 -
was an “innocuous substance and that it is difficult to tell whether the gasoline
smells at 500 ppm or 2000 ppm”. In another experimental study, dated 1960,
volunteers were exposed in a chamber to up to 1000 ppm gasoline vapor for 30
min (46). Eye irritation was the only significant effect seen both by ratings and by
the change in the pattern of conjunctival blood vessels as determined from
photographs.
6.4.3 Possible Sources of Error
“As scientists it is our duty to maximize the amount of relevant information
gathered from volunteer studies” (40). In the present studies, to achieve this aim,
the acute effects were measured during the same exposure session as the
toxicokinetic variables. This limits the number of exposure occasions and indeed
the number of subjects, as only two subjects at a time can be exposed if samples
of blood and exhaled air are to be taken. Therefore, the number of experimental
subjects was by necessity few and this unfortunately reduces the power of the
acute effect study. Further, the subjects were a homogenous group of healthy
white men. There was a possibility of further selection bias in the volunteer
recruitment as sensitive individuals may avoid participating because of previous
negative experiences with volatile chemicals or odors in general. Since we seek
volunteers by advertising, the magnitude of this possible self-selection bias is
unknown. Hence, oxygenate-related effects may have escaped unnoticed in the
present study because of the small group, exclusion of sensitive individuals in the
sample population and the relatively short exposure duration. On the other hand,
the exposure conditions used (up to 50 ppm) are at least one order of magnitude
higher than expected environmental exposure levels for the general public.
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To compare the acute effects of two chemicals such as ETBE and MTBE it
would obviously be best to expose the same volunteers in a randomized blinded
trial. However, as two years passed between these two studies and because the
experiments are rather extensive and time-consuming for the volunteers, we
judged it difficult to successfully recruit all 10 subjects for a second exposure
series. Instead we chose to recruit new volunteers for the ETBE study, excluding
those that had already participated in the MTBE study.
Further confounding factors in acute effect studies in general are e.g., air
pollution and pollen. In the present studies, at least pollen was not a matter of
concern, since these studies were performed during the autumn and winter
seasons (September through March). However, other forms of air pollution could
confound these kinds of studies.
Physical exercise may confound the battery of tests for acute effects, especially
the pulmonary function test (92). However in the ETBE study it is clear that the
exposure and not the physical activity gave the minor lung function impairments,
since these effects were not seen during the control exposure.
In occupational settings people are often exposed to a mixture of substances
and gasoline is indeed a complex mixture. This may entail variations in terms of
both toxicokinetics and acute effects. Any single chemical could have
independent, additive, synergistic, antagonistic or potentiating effects when
combined with any other (172). Chemical interactions between the oxygenates
and other components of gasoline have hitherto not been considered in these or
other exposure studies (33, 130, 135, 140), since volunteers were exposed to the
oxygenates alone. The acute health complaints seen after environmental exposure
to gasoline containing MTBE may perhaps be explained by a combination effect
between MTBE and other compounds in the gasoline, or possibly with some other
environmental contaminant. It is also a possibility that MTBE in gasoline may
have acute effects on particularly sensitive individuals under some special
circumstances. However, there is a high degree of confidence in the conclusion
that MTBE-containing fuels are not a cause of acute toxicity in the general
population (14).
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7. Conclusions
Experimental toxicokinetics:
• A moderate respiratory uptake and a high respiratory excretion was seen for the
ethers compared to many other solvents. MTBE showed a higher uptake, lower
respiratory excretion and a faster terminal elimination in blood compared with
ETBE.
• Two additional metabolites, α-hydroxyisobutyric acid (HBA) and 2-methyl-1,2-
propanediol (MPD), were characterized in urine by 13C-NMR after exposure to
[1,2-13C2]-MTBE.
• Acetone level in blood (detected by GC) was higher after ETBE exposures
compared to control exposure, and acetone is probably partly formed from ETBE.
• Urinary excretion of MTBE, ETBE and TBA was low, below 1% of the ether
uptake, however, markedly higher amounts of HBA and MPD were found in the
urine.
• Linear kinetics was seen after exposure up to 50 ppm MTBE and ETBE.
PBTK modeling:
• Physical activity has a profound influence on the internal exposure.
• ETBE, as well as lesser amounts of TBA accumulate in a small extent in tissues
during a week of repeated exposure.
• The levels of TBA in blood, urine and exhaled air were less influenced by
fluctuations in the exposure levels than were the amount of ETBE in blood and
exhaled air (especially at the end of the workshift).
• Inter individual variability (eight subjects) in biomarker levels is higher the next
morning than at the end of the workshift, and higher for TBA than for ETBE.
• The concentration of TBA in urine is a suitable biological exposure marker for
ether and gasoline vapor. However, other metabolites that are excreted in higher
amounts in the urine (e.g., HBA), may be even better candidates as biomarkers.
Acute effect test battery:
• Elevated ratings of discomfort in the throat and airways were recorded at 50 ppm
ETBE.
• Minor impairment in pulmonary function was seen after ETBE exposure at 25
and 50 ppm (lung function tests were not performed in the MTBE study).
• Nasal swelling (MTBE and ETBE) and an increased blinking frequency (ETBE)
was seen. Still, these effects did not correlate with exposure levels and may not be
related to the oxygenate exposure.
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8. Summary
Nihlén, A. Ethers as Gasoline Additives: Toxicokinetics and Acute Effects in
Humans. Arbete och Hälsa 1998; 28.
Ethers or other oxygen-containing compounds are used as replacements for lead
in gasoline and to ensure complete combustion. Methyl tertiary-butyl ether
(MTBE) is already in use world-wide and ethyl tertiary-butyl ether (ETBE) may
be used increasingly in the future. The aims of the present thesis were to study the
uptake and disposition (toxicokinetics) of MTBE and ETBE in humans, to
address the issue of biological monitoring and to measure acute effects (assessed
by questionnaire, lung function, nasal and ocular measurements).
Healthy male volunteers were experimentally exposed during 2 h to vaporized
MTBE (5, 25 and 50 ppm, n=10) or ETBE (0, 5, 25 and 50 ppm, n=8) in a
chamber (whole-body) and 13C-labeled MTBE (50 ppm, n=4) via a face-mask.
The toxicokinetics of MTBE and ETBE in humans were quite similar, judging
from breath, blood and urine profiles. However, the respiratory uptake of MTBE
was higher (45% MTBE and 33% ETBE) and respiratory exhalation of
unmetabolized MTBE was lower (38% MTBE and 47% ETBE) compared to
ETBE. Linear kinetics was seen for the ethers and TBA up to 50 ppm. Low
urinary excretion of unmetabolized ether (<0.1%) and of a metabolite, tertiary-
butyl alcohol (TBA) (<1%), was seen. After 13C-labeled MTBE exposure two
urinary metabolites, 2-methyl-1,2-propanediol and α-hydroxyisobutyric acid,
were characterized by 13C-NMR. These metabolites were excreted in markedly
higher amounts than TBA.
A physiologically based toxicokinetic model was developed for ETBE using
the determined partition coefficients and data from the chamber exposure. The
model indicates that workload has a profound influence on internal dose. TBA
excretion seemed to be less sensitive to fluctuations in exposure levels compared
to the ether, especially in samples taken at the end of a workshift. Only a small
accumulation of ether and TBA in the body was seen throughout a week of
repeated exposure.
MTBE vapor had very small or no effects up to 50 ppm. After ETBE exposure,
elevated ratings of irritation in the throat and airways (50 ppm), and, in addition,
minor pulmonary function impairments were seen (25 and 50 ppm ETBE, lung
measures not performed for MTBE). This effect as such is not of clinical concern
in healthy individuals. However, it cannot be excluded that other subjects may
show more severe reactions.
In conclusion, the toxicokinetic results as well as considering practical issues
(i.e. sampling and analysis), implies that the concentration of TBA in urine is a
good biological exposure marker for ether and gasoline vapor. However, further
studies of other metabolites that are excreted in higher amounts in the urine (e.g.,
α-hydroxyisobutyric acid), may identify even more suitable candidates as
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biomarkers. The knowledge about the toxicokinetics and acute effects of MTBE
and ETBE in humans presented in this thesis is relevant in e.g., risk assessments.
Key words: acute effects, biological monitoring, ethyl tertiary-butyl ether, ETBE,
man, methyl tertiary-butyl ether, MTBE, oxygenate, petrol, physiologically based
toxicokinetic model, PBTK, PBPK, tertiary-butyl alcohol, TBA, toxicokinetics.
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9. Sammanfattning (Summary in Swedish)
Nihlén, A. Ethers as Gasoline Additives: Toxicokinetics and Acute Effects in
Humans. Arbete och Hälsa 1998; 28.
Etrar eller andra ämnen som innehåller syre används i bensin för att ersätta bly
och förbättra förbränningen. Metyl tertiär-butyl eter (MTBE) används globalt,
men kan komma att ersättas av etyl tertiär-butyl eter (ETBE). Syftet med studien
var att studera MTBE och ETBEs upptag och omsättning (toxikokinetik) hos
människa, relatera till biologiska exponeringsmarkörer och mäta akuta effekter
(frågeformulär, lungfunktion, näs- och ögonmätningar).
Friska frivilliga män exponerades i 2 timmar under lätt arbete dels för förångad
MTBE (5, 25 och 50 ppm) eller ETBE (0, 5, 25 och 50 ppm) i en kammare och
dels för 13C-märkt MTBE (50 ppm) via en ansiktsmask.
Blod-, utandnings- och urinprofiler av MTBE och ETBE hos människa visade
på likartad toxikokinetik för båda ämnena. Dock var upptaget av MTBE högre
(45% MTBE och 33% ETBE) och utandningen av ometaboliserad MTBE lägre
(38% MTBE och 47% ETBE) än för ETBE. Etrar och TBA följde linjär kinetik
upp till 50 ppm. Urinutsöndringen av eter (<0.1%) och av en metabolit, tertiär-
butyl alkohol (TBA) (<1%), var låg. Efter 13C-märkt MTBE exponering
identifierades två urinmetaboliter, 2-metyl-1,2-propandiol och α-hydroxi
isosmörsyra, med 13C-NMR. Dessa metaboliter utsöndrades i högre grad i urin
jämfört med TBA.
En fysiologiskt baserad toxikokinetisk modell utvecklades för ETBE med hjälp
av fördelningskvoter och data från de tre ETBE exponeringarna. Modellen
indikerade att arbetsbelastningen har en betydande inverkan på den interna
kroppsdosen. TBA verkade vara mindre känslig för fluktuationer i
exponeringsnivån jämfört med etern, speciellt vid slutet av ett arbetspass. Endast
en liten ackumulering av eter och TBA i kroppen observerades efter en veckas
upprepad exponering.
Minimala akuta effekter observerades efter exponering upp till 50 ppm MTBE.
Efter ETBE exponering observerades förhöjda skattningar av obehag i svalg, hals
eller luftvägar (50 ppm) samt en något försämrad lungfunktion (25 och 50 ppm
ETBE, lungfunktionsmätningar utfördes ej efter MTBE exponering). Den lätta
försämringen har ingen klinisk relevans som sådan, men det kan inte uteslutas att
andra individer kan reagera betydligt kraftigare än dessa få och friska män.
Sammanfattningsvis, de toxikokinetiska resultaten samt hänsyn till praktisk
användning (vid t.ex. provtagning och analys) visar att halten av TBA i urin är en
lämplig biologisk exponeringsmarkör för bensinånga. Men studier av andra
urinmetaboliter, som utsöndras i högre halter än TBA (t.ex. α-hydroxi
isosmörsyra), kan möjligen identifieras vara ännu bättre biomarkörer.
Informationen om MTBE och ETBEs toxikokinetik och akuta effekter hos
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människa, som har presenterats i denna avhandling, är relevant vid t.ex.
riskbedömningar.
Nyckelord: akuta effekter, bensin, biologisk monitorering, etyl tertiär-butyl eter,
ETBE, fysiologiskt baserad toxikokinetisk modell, metyl tertiär-butyl eter,
MTBE, människa, oxygenat, PBTK, PBPK, tertiär-butyl alkohol, TBA
toxikokinetik.
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